
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs3.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>SUMOylation of AnxA6 facilitates EGFR-PKC&#945; complex formation to suppress epithelial cancer growth - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="939BE807DB0F4BC500002A7B9FE469BE.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="cellcom" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC10391975/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391975/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Cell Communication and Signaling : CCS" /><meta name="citation_title" content="SUMOylation of AnxA6 facilitates EGFR-PKC&#x003b1; complex formation to suppress epithelial cancer growth" /><meta name="citation_author" content="Zenghua Sheng" /><meta name="citation_author_institution" content="Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China" /><meta name="citation_author" content="Xu Cao" /><meta name="citation_author_institution" content="Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China" /><meta name="citation_author" content="Ya-nan Deng" /><meta name="citation_author_institution" content="Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China" /><meta name="citation_author" content="Xinyu Zhao" /><meta name="citation_author_institution" content="Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China" /><meta name="citation_author" content="Shufang Liang" /><meta name="citation_author_institution" content="Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China" /><meta name="citation_publication_date" content="2023" /><meta name="citation_volume" content="21" /><meta name="citation_doi" content="10.1186/s12964-023-01217-x" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC10391975/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC10391975/" /><meta name="citation_pmid" content="37528485" /><meta name="DC.Title" content="SUMOylation of AnxA6 facilitates EGFR-PKC&#x003b1; complex formation to suppress epithelial cancer growth" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="BMC" /><meta name="DC.Contributor" content="Zenghua Sheng" /><meta name="DC.Contributor" content="Xu Cao" /><meta name="DC.Contributor" content="Ya-nan Deng" /><meta name="DC.Contributor" content="Xinyu Zhao" /><meta name="DC.Contributor" content="Shufang Liang" /><meta name="DC.Date" content="2023" /><meta name="DC.Identifier" content="10.1186/s12964-023-01217-x" /><meta name="DC.Language" content="en" /><meta property="og:title" content="SUMOylation of AnxA6 facilitates EGFR-PKC&#x003b1; complex formation to suppress epithelial cancer growth" /><meta property="og:type" content="article" /><meta property="og:description" content="The Annexin A6 (AnxA6) protein is known to inhibit the epidermal growth factor receptor (EGFR)-extracellular signal regulated kinase (ERK)1/2 signaling upon EGF stimulation. While the biochemical mechanism of AnxA6 inactivating phosphorylation of EGFR ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391975/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10391975/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/221/">Cell Commun Signal</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/425134/">v.21; 2023</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10391975
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10391975/pdf/12964_2023_Article_1217.pdf" class="int-view">PDF (4.4M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10391975/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10391975/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10391975" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10391975%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="Wlxyz964DxFAS5GVkguGTCJ9ZG93nVMcSjGeKegnGqgVj4UaMrWdJ7dSxPAoi2eD">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10391975%2F&amp;text=SUMOylation%20of%20AnxA6%20facilitates%20EGFR-PKC%003B1%20complex%20formation%20to%20suppress%20epithelial%20cancer%20growth" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10391975%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391975/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10391975/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37528485/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10391975/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37528485/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10391975/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10391975/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/221/">Cell Commun Signal</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/425134/">v.21; 2023</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10391975
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-cellcom.png" alt="Logo of cellcom" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://biosignaling.biomedcentral.com/" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Cell Commun Signal.</span> 2023; 21: 189. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2023 Aug 1. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1186%2Fs12964-023-01217-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/s12964-023-01217-x</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC10391975</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37528485">37528485</a></div></div></div><h1 class="content-title">SUMOylation of AnxA6 facilitates EGFR-PKC&#x003b1; complex formation to suppress epithelial cancer growth</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sheng%20Z%5BAuthor%5D" class="affpopup" co-rid="_co_idm140614426496640" co-class="co-affbox">Zenghua Sheng</a>,<sup></sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cao%20X%5BAuthor%5D" class="affpopup" co-rid="_co_idm140614382234704" co-class="co-affbox">Xu Cao</a>,<sup></sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Deng%20Yn%5BAuthor%5D" class="affpopup" co-rid="_co_idm140614432478816" co-class="co-affbox">Ya-nan Deng</a>,<sup></sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhao%20X%5BAuthor%5D" class="affpopup" co-rid="_co_idm140614432477408" co-class="co-affbox">Xinyu Zhao</a>,<sup></sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Liang%20S%5BAuthor%5D" class="affpopup" co-rid="_co_idm140614432475888" co-class="co-affbox">Shufang Liang</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup></sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140614426496640"><h3 class="no_margin">Zenghua Sheng</h3><p>Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sheng%20Z%5BAuthor%5D">Zenghua Sheng</a></div></div><div id="_co_idm140614382234704"><h3 class="no_margin">Xu Cao</h3><p>Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Cao%20X%5BAuthor%5D">Xu Cao</a></div></div><div id="_co_idm140614432478816"><h3 class="no_margin">Ya-nan Deng</h3><p>Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Deng%20Yn%5BAuthor%5D">Ya-nan Deng</a></div></div><div id="_co_idm140614432477408"><h3 class="no_margin">Xinyu Zhao</h3><p>Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhao%20X%5BAuthor%5D">Xinyu Zhao</a></div></div><div id="_co_idm140614432475888"><h3 class="no_margin">Shufang Liang</h3><p>Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China </p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Liang%20S%5BAuthor%5D">Shufang Liang</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140614428322640_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140614428322640_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140614428322640_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140614428322640_ai" style="display:none"><div class="fm-affl" id="Aff1">Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17, Section 3 of Renmin South Road, 610041 Chengdu, People&#x02019;s Republic of China </div><div><span class="fm-affl">Shufang Liang, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="nc.ude.ucs@6002iziz" class="oemail">nc.ude.ucs@6002iziz</a></span>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div></div><div class="fm-article-notes hide half_rhythm" id="idm140614428322640_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2023 Mar 22; Accepted 2023 Jul 6.</div></div><div class="permissions half_rhythm hide" id="idm140614428322640_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; The Author(s) 2023</div><div class="license half_rhythm"><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="https://creativecommons.org/publicdomain/zero/1.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Additional file 1</strong>.</div><div><a href="/pmc/articles/PMC10391975/bin/12964_2023_1217_MOESM1_ESM.zip" data-ga-action="click_feat_suppl">12964_2023_1217_MOESM1_ESM.zip</a><span style="color:gray"> (272M)</span></div><div class="small guid">GUID: 0989D0D8-6BB3-423B-A673-7C84167184B5</div></div></dd></dl><dl data-length="139" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p>The MS proteomics data and the search data by MaxQuant is available in the Mendeley Data (<a href="https://data.mendeley.com/datasets/rdw3fk6cng/1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://data.mendeley.com/datasets/rdw3fk6cng/1</a>).</p></dd></dl></div><div id="Abs1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="Abs1title">Abstract</h2><!--article-meta--><div><div id="sec-a.p.b.m.a" class="sec sec-first"><h3 id="sec-a.p.b.m.atitle">Background</h3><p id="Par1" class="p p-first-last">The Annexin A6 (AnxA6) protein is known to inhibit the epidermal growth factor receptor (EGFR)-extracellular signal regulated kinase (ERK)1/2 signaling upon EGF stimulation. While the biochemical mechanism of AnxA6 inactivating phosphorylation of EGFR and ERK1/2 is not completely explored in cancer cells.</p></div><div id="sec-a.p.b.m.b" class="sec"><h3 id="sec-a.p.b.m.btitle">Methods</h3><p id="Par2" class="p p-first-last">Cells were transiently co-transfected with pFlag-AnxA6, pHA-UBC9 and pHis-SUMO1 plasmids to enrich the SUMOylated AnxA6 by immunoprecipitation, and the modification level of AnxA6 by SUMO1 was detected by Western blot against SUMO1 antibody. The SUMOylation level of AnxA6 was compared in response to chemical SUMOylation inhibitor treatment. AnxA6 SUMOylation sites were further identified by LC&#x02013;MS/MS and amino acid site mutation validation. AnxA6 gene was silenced through AnxA6 targeting shRNA-containing pLKO.1 lentiviral transfection in HeLa cells, while AnxA6 gene was over-expressed within the Lenti-Vector carrying AnxA6 or mutant AnxA6<sup>K299R</sup> plasmid in A431 cells using lentiviral infections. Moreover, the mutant plasmid pGFP-EGFR<sup>T790M/L858R</sup> was constructed to test AnxA6 regulation on EGFR&#x000a0;mutation-induced signal transduction. Moreover, cell proliferation, migration, and gefitinib chemotherapy sensitivity were evaluated in HeLa and A431 cells under AnxA6 konckdown or AnxA6 overexpression by CCK8, colony form and wound healing assays. And tumorigenicity in vivo was measured in epithelial cancer cells-xenografted nude mouse model.</p></div><div id="sec-a.p.b.m.c" class="sec"><h3 id="sec-a.p.b.m.ctitle">Results</h3><p id="Par3" class="p p-first-last">AnxA6 was obviously modified by SUMO1 conjugation within Lys (K) residues, and the K299 was one key SUMOylation site of AnxA6 in epithelial cancer cells. Compared to the wild type AnxA6, AnxA6 knockdown and its SUMO site mutant AnxA6<sup>K299R</sup> showed less suppression of dephosphorylation of EGFR-ERK1/2 under EGF stimulation. The SUMOylated AnxA6 was prone to bind EGFR in response to EGF inducement, which facilitated EGFR-PKC&#x003b1; complex formation to decrease the EGF-induced phosphorylation of EGFR-ERK1/2 and cyclin D1 expression. Similarly, AnxA6 SUMOylation inhibited dephosphorylation of the mutant EGFR, thereby impeding EGFR&#x000a0;mutation-involved signal transduction. Moreover, AnxA6 knockdown or the K299 mutant AnxA6<sup>K299R</sup> conferred AnxA6 inability to suppress tumor progression, resulting in drug resistance to gefitinib in epithelial cancer cells. And in epithelial cancer cells-xenografted nude mouse model, both the weight and size of tumors derived from AnxA6 knockdown or AnxA6<sup>K299R</sup> mutation-expressing cells were much greater than that of AnxA6-expressing cells.</p></div><div id="sec-a.p.b.m.d" class="sec"><h3 id="sec-a.p.b.m.dtitle">Conclusions</h3><p id="Par4" class="p p-first">Besides EGFR gene mutation, protein SUMOylation modification of EGFR-binding protein AnxA6 also functions pivotal roles in mediating epithelial cancer cell growth and gefitinib drug effect.</p><p id="Par500" class="p p-last">
<span class="sup-box" id="MOESM2"><a href="/pmc/articles/PMC10391975/bin/12964_2023_1217_MOESM2_ESM.mp4" data-ga-action="click_feat_suppl">Video Abstract</a> video file.<sup>(76M, mp4)</sup></span></p></div><div id="sec-a.p.b.m.e" class="sec sec-last"><h3 id="sec-a.p.b.m.etitle">Supplementary Information</h3><p class="p p-first-last">The online version contains supplementary material available at 10.1186/s12964-023-01217-x.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Annexin A6, SUMOylation, EGFR, Gefitinib</span></div></div><div id="Sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec1title">Background</h2><p id="Par23" class="p p-first">SUMOylation is one type of post-translational modifications (PTMs) [<a href="#CR1" rid="CR1" class=" bibr popnode">1</a>] to regulate multiple cellular processes and functions. SUMOylation confers a small ubiquitin-like modifier (SUMO) protein conjugation to a lysine (K) residue of the target protein [<a href="#CR2" rid="CR2" class=" bibr popnode">2</a>]. The reversible attachment of a SUMO to a protein is controlled by an enzymatic reaction pathway that is analogous to the ubiquitin modification [<a href="#CR3" rid="CR3" class=" bibr popnode">3</a>]. SUMOylation is a dynamic process which mediates biological activities of the substrate protein including subcellular distribution, protein stability and activity, and interaction with other proteins [<a href="#CR4" rid="CR4" class=" bibr popnode">4</a>]. The imbalance of SUMOylation is tightly associated with cancer occurrence and progression [<a href="#CR3" rid="CR3" class=" bibr popnode">3</a>&#x02013;<a href="#CR10" rid="CR10" class=" bibr popnode">10</a>].</p><p id="Par24">The epithelial growth factor receptor (EGFR)&#x000a0;is a cell surface glycoprotein designated the EGF receptor belonging to ErbB family of tyrosine kinase and has been shown to have an active role in a variety of tumor development [<a href="#CR11" rid="CR11" class=" bibr popnode">11</a>, <a href="#CR12" rid="CR12" class=" bibr popnode">12</a>]. The carboxy terminal tyrosine residues of EGFR, tyrosine 1068 and tyrosine 1173, are the major sites of autophosphorylation, which occurs as a result of EGF binding. Once being activated, EGFR initiates a cascade of downstream signaling pathways including RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, thereby regulating cell proliferation, survival, and differentiation [<a href="#CR13" rid="CR13" class=" bibr popnode">13</a>].</p><p id="Par25">This high incidence of EGFR-related cancers and its association with poor clinical outcomes pave way for development of therapeutic interventions, including small-molecule tyrosine kinase inhibitors (TKIs), including the first-generation gefitinib, erlotinib and icotinib, the second-generation afatinib and dacomitinib and the third-generation osimertinib [<a href="#CR14" rid="CR14" class=" bibr popnode">14</a>, <a href="#CR15" rid="CR15" class=" bibr popnode">15</a>].&#x000a0;The first generation TKIs are typically used to treat patients with high EGFR expression who carry L858R or exon 19 deletion mutations but were resisted by a second mutation&#x000a0;T790M. Second generation or third-generation TKIs are effective against&#x000a0;T790M&#x000a0;EGFR. However,&#x000a0;primary or acquired resistance&#x000a0;to TKIs seems inevitable and severely hinders patients from getting further benefits from treatment [<a href="#CR16" rid="CR16" class=" bibr popnode">16</a>&#x02013;<a href="#CR18" rid="CR18" class=" bibr popnode">18</a>]. Interestingly, the presence or absence of some scaffold proteins like Akt kinase-interacting protein 1 and caveolin, are known to recruit positive or negative regulators of the EGFR to modulate their signal output and alter sensitivity toward drugs targeting the EGFR [<a href="#CR19" rid="CR19" class=" bibr popnode">19</a>, <a href="#CR20" rid="CR20" class=" bibr popnode">20</a>]. Hence, as the relative amounts of scaffolds can substantially influence the strength of EGFR signaling networks, this has potential to alter TKI efficacy.</p><p id="Par26">Annexin A6 (AnxA6) acts as a multifunctional scaffold protein by recruiting several signaling proteins, modulating actin dynamics and mediating the endosome aggregation or vesicle fusion in secreting epithelia during exocytosis [<a href="#CR21" rid="CR21" class=" bibr popnode">21</a>]. More interestingly, AnxA6 exhibits dual functions either as a tumor suppressor or oncogene in carcinogenesis [<a href="#CR22" rid="CR22" class=" bibr popnode">22</a>&#x02013;<a href="#CR31" rid="CR31" class=" bibr popnode">31</a>], which is dependent on its recruitment of different target proteins to involve in cancer cell activities. AnxA6 displays cancer suppression effects on A431 cells by interacting with protein kinase C&#x003b1; (PKC&#x003b1;) to reduce EGF-induced tyrosine phosphorylation of EGFR (pY-EGFR) and cycling D1 expression [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>&#x02013;<a href="#CR26" rid="CR26" class=" bibr popnode">26</a>]. Similarly, knockdown of AnxA6 enhances phosphorylation of ERK1/2 following EGF stimulation and regulates EGFR/Ras signaling pathway in HeLa cells [<a href="#CR26" rid="CR26" class=" bibr popnode">26</a>]. However, AnxA6 acts as a promoting factor in invasiveness of breast cancer [<a href="#CR29" rid="CR29" class=" bibr popnode">29</a>, <a href="#CR30" rid="CR30" class=" bibr popnode">30</a>] and acute lymphoblastic leukemia [<a href="#CR31" rid="CR31" class=" bibr popnode">31</a>].</p><p id="Par27">Considering a multi-faced scaffolding role of AnxA6, we speculate it exerts biological function not only through interacting with specific proteins but also by ways of PTMs. As an example of our recent findings, it has been confirmed another adaptor protein IQGAP1 is much SUMOylated in colorectal cancer. The SUMOylated IQGAP1 enhances colorectal cancer cell growth, cell migration and tumorigenesis in vitro and in vivo through activating the phosphorylation of ERK, MEK and AKT [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>]. However, which kind of PTMs on AnxA6 and how to regulate biological process are rarely known in cancer cells.</p><p id="Par28" class="p p-last">In this study, we have revealed AnxA6 is modified by SUMO1 in epithelial cancer cells including A431 and HeLa. SUMOylation of AnxA6 at K299 residue facilitates the binding of PKC&#x003b1; to EGFR and subsequently impedes the EGFR activity. Compared to the wild-type AnxA6, AnxA6 knockdown or the K299 mutant AnxA6<sup>K299R</sup> up-regulates the phosphorylation level of EGFR-ERK1/2 under EGF stimulation, thereby promoting epithelial cell proliferation and migration. Meanwhile, AnxA6 SUMOylation suppresses dephosphorylation of EGFR mutations (particularly&#x000a0;T790M&#x000a0;and&#x000a0;L858R&#x000a0;double mutation), thereby impeding EGFR&#x000a0;mutation-involved signal transduction. Moreover, the EGFR tyrosine kinase inhibitor gefitinib more effectively inhibits cell viability, clonogenic growth, and wound healing of the wild type AnxA6 cells compared to AnxA6 knockdown cells or the K299 mutant AnxA6<sup>K299R</sup> cells. Collectively, AnxA6 SUMOylation plays a critical role in mediating EGFR-PKC&#x003b1; complex formation to suppress phosphorylation of EGFR-ERK1/2 signaling pathway, which much effectively enables gefitinib to inhibit proliferation and migration of epithelial cancer cells.</p></div><div id="Sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec2title">Materials and methods</h2><div id="Sec3" class="sec sec-first"><h3 id="Sec3title">Reagents and antibodies</h3><p id="Par29" class="p p-first-last">Cell culture media DMEM and RPMI-1640, fetal bovine serum (FBS) were ordered from Gibco. Human recombinant EGF (Catalog number:10605-HNAE) was bought from Sino Biological company. ML792 (HY-108702), SUMOylation inhibitor 2-D08 (HY-114166), gefitinib (HY-50895), puromycin (HY-B1743A) and N-ethylmaleimide (NEM) (HY-D0843), were ordered from MedChemexpress company. Slurry anti-Flag M2 affinity gel (A2220) was ordered from Sigma. The protein-A beads (161&#x02013;4013) were bought from Bio-Rad. The primary antibodies included individual monoclonal antibody of Myc (ab18185, Abcam), EGFR (sc-373746, Santa Cruz), AnxA6 (sc-166807, Santa Cruz). And rabbit monoclonal antibodies against Flag (BX00086), HA (BX00069-C3), His (BX00085-C3), SUMO1(ET1606-53), UBC9(ET1610-21), pY-EGFR(1086) (ET1612-30) and p-ERK1/2 (ET1610-13), ERK1/2 (ET1601-29), Cyclin D1(SA38-08) were all ordered from HuaBio Company in China. The antibody of &#x003b2;-tubulin (TA-10, Zsbio) and &#x003b2;-actin (TA-09, Zsbio) was used to quantify expression of housekeeping gene &#x003b2;-tubulin or &#x003b2;-actin for comparison normalization. The IgG antibody (A7016, Beyotime) was taken as nonspecific binding control for IP performance.</p></div><div id="Sec4" class="sec"><h3 id="Sec4title">Cell culture</h3><p id="Par30" class="p p-first-last">HEK293T, HeLa and A431 cell lines were cultured with DMEM or RPMI-1640 medium including 10% FBS and 100 unit&#x02019;s penicillin&#x02013;streptomycin in a 37&#x000a0;&#x000b0;C incubator with 5% CO<sub>2</sub> and 95% air.</p></div><div id="Sec5" class="sec"><h3 id="Sec5title">Plasmids transfection and generation of stable cell lines</h3><p id="Par31" class="p p-first">The AnxA6 cDNA (gi71773329) was cloned into a eukaryotic expression vector pTango-zeo which contains a Flag tag, and the recombinant plasmid named pFlag-AnxA6 was verified by DNA sequencing. The mutant plasmids, including pFlag-AnxA6<sup>K75R</sup>, pFlag-AnxA6<sup>K306R</sup>, pFlag-AnxA6<sup>K418R</sup>, pFlag-AnxA6<sup>K579R</sup>, pFlag-AnxA6<sup>K156R</sup>,pFlag-AnxA6<sup>K299R</sup> and pFlag-AnxA6<sup>K314R</sup> were derived from pFlag-AnxA6 through site mutagenesis performed by Genecopoeia Company, and all mutations were confirmed by DNA sequencing. The plasmids pHis-SUMO1, pHis-SUMO2, pHis-SUMO3, pMyc-SUMO1, and pHA-UBC9 were used and stored in our laboratory [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>]. And the plasmids pMD2.G and pSPAX2 were provided by Beijing Tsingke Biotech Co., Ltd.</p><p id="Par32">The mutant plasmid pGFP-EGFR<sup>T790M/L858R</sup>, with double mutations of T790 mutation to M and L858 mutation to R, was derived from pGFP-EGFR [<a href="#CR32" rid="CR32" class=" bibr popnode">32</a>] through site mutagenesis performed by Beijing Tsingke Biotech Co., Ltd., which was confirmed by DNA sequencing. To construct an expression plasmid with specific shRNAs targeting AnxA6 (shRNA-AnxA6), primer pairs containing shRNA-AnxA6 sequences were mixed, annealed and inserted into the pLKO.1 Lenti vector, and the recombinant plasmid was named pLKO.1-shRNA-AnxA6.</p><p id="Par33" class="p p-last">Plasmids were transiently transfected into HEK293T, HeLa and A431 cells with the transfection reagent of Lipofectamine2000 (11,668&#x02013;019, Life Technologies) to observe biological effects. For generation of AnxA6-overexpressing cells, HEK293T cells are co-transfected with pMD2.G, pSPAX2, and pFlag-AnxA6 or pFlag-AnxA6<sup>K299R</sup> plasmids, after transfection of 72&#x000a0;h, 10&#x000a0;mL lentivirus-containing medium was collected to infect target cells, following stable cells were screened with 2&#x000a0;&#x003bc;g/ml puromycin for two weeks. Similarly, plasmids pMD2.G, pSPAX2, and pLKO.1-shRNA-AnxA6 were co-transfected into HEK293T cells to generate and screen stable AnxA6-knockdown cells with 2&#x000a0;&#x003bc;g/ml puromycin for two weeks.</p></div><div id="Sec6" class="sec"><h3 id="Sec6title">Immu<em>noprecipitation</em></h3><p id="Par34" class="p p-first-last">2&#x02009;&#x000d7;&#x02009;10<sup>7</sup> cells were harvested to extract total proteins to enrich the target protein by immunoprecipitation (IP) mainly according to our previous approaches [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>]. The supernatant of lysates with approximately containing 1&#x02013;2&#x000a0;mg protein were incubated with 50&#x000a0;&#x003bc;l of slurry anti-Flag M2 affinity gel overnight at 4&#x000a0;&#x000b0;C. To capture AnxA6 protein, 2&#x000a0;mg cellular supernatant was incubated with the anti-AnxA6 antibody and the protein-A beads overnight. As a negative control, the normal rabbit IgG was performed IP to eliminate the nonspecific protein binding. After washing 4 times with TBS buffer, the protein complexes were eluted with the sample-loading buffer to run SDS-PAGE for Western blot detection.</p></div><div id="Sec7" class="sec"><h3 id="Sec7title">Western blot</h3><p id="Par35" class="p p-first-last">Cell lysates or protein samples from IP were separated on a 7.5&#x02013;12.5% SDS-PAGE gel to test the protein expression abundance by Western blot against specific antibodies. The specific primary antibodies included anti-Flag (BX00086, HuaBio), anti-SUMO1 (ET1606-53, HuaBio), anti-AnxA6 (sc-166807, Santa Cruz) and anti-&#x003b2;-actin (TA-09, Zsbio) antibodies. The PVDF membranes were blocked in 5% nonfat milk at room temperature for 1.5&#x000a0;h and then incubated with specific primary antibodies at 4&#x02103; overnight. The corresponding secondary antibody was incubated with the PVDF membrane for 1&#x000a0;h at room temperature. The protein bands were visualized by enhanced chemiluminescence (Millipore, USA) and analyzed using ImageJ software.</p></div><div id="Sec8" class="sec"><h3 id="Sec8title">Cell proliferation</h3><p id="Par36" class="p p-first-last">Cell proliferation was analyzed by CCK8 according to our previous methods [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>, <a href="#CR33" rid="CR33" class=" bibr popnode">33</a>]. After cell transfection for 24&#x000a0;h, 2&#x02009;&#x000d7;&#x02009;10<sup>3</sup> Hela or A431 cells/well were seeded into a 96-well plate to incubate for up to 120&#x000a0;h with medium replenished every 48&#x000a0;h. Cells were cultured in DMEM or RPMI-1640 containing 0.1% (v/v) FBS and 100&#x000a0;ng/ml EGF to measure cell proliferation using CCK8 approach. Moreover, colony-forming assays were performed as described [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>], and 1000 cells were grown in 6-well plates with 0.1% (v/v) FBS and 100&#x000a0;ng/ml EGF treated for 14&#x000a0;days.</p></div><div id="Sec9" class="sec"><h3 id="Sec9title">Wound healing assays</h3><p id="Par37" class="p p-first-last">The A431 cells were seeded into a 6-wells plate at an appropriate concentration. After being transfected with pFlag-AnxA6 or pFlag-AnxA6<sup>K299R</sup> plasmids for 24&#x000a0;h, then a scratch was made across the center of each well [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>, <a href="#CR14" rid="CR14" class=" bibr popnode">14</a>]<sup>.</sup> And Cells were washed with PBS three times to remove the detached cells. After cells were allowed to grow for 36&#x000a0;h in RPMI-1640 containing 0.1% (v/v) FBS and 100&#x000a0;ng/ml EGF, wound margins were photographed and cell migration was observed under an inverted microscope.</p></div><div id="Sec10" class="sec"><h3 id="Sec10title">Liquid chromatography with tandem mass spectrometry (LC&#x02013;MS/MS)</h3><p id="Par38" class="p p-first-last">HEK293T cells overexpressing AnxA6 and SUMO1<sup>T95K</sup>, were collected to enrich SUMO1-tagging AnxA6 by IP [<a href="#CR34" rid="CR34" class=" bibr popnode">34</a>]. The&#x000a0;sample was eluded for digesting by Lys-C enzyme, and peptides were identified by liquid chromatography-tandem mass spectrometry(LC&#x02013;MS/MS) on an easy nano-LC1000 HPLC system (Thermo Scientific, San Jose, CA) and a Q-Exactive mass spectrometry (Thermo Scientific, San Jose, CA) [<a href="#CR35" rid="CR35" class=" bibr popnode">35</a>, <a href="#CR36" rid="CR36" class=" bibr popnode">36</a>]. Survey scan ranged 300&#x02013;1800&#x000a0;m/z at a resolution of 70,000. After full scan, top 10 MS fragments were selected for higher-energy collisional dissociation. Isolation window was acquired at a resolution of 17,500 with an isolation window of 1.6&#x000a0;m/z. The MS/MS scan was 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> with a maximum injection time of 20&#x000a0;ms, and that for the MS/MS scan was 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> with a maximum injection time of 100&#x000a0;ms.The data were searched by MaxQuant search engine (version 2.2, Matrix Sciences, London, UK). Parameters were chosen as follows: the human Swiss-Prot database (version 2019.12), up to two missed cleavage sites for Lys-C, peptide mass tolerance of 7&#x000a0;ppm, and fragment mass tolerance of 0.5&#x000a0;Da for the higher-energy collisional dissociation (HCD) [<a href="#CR36" rid="CR36" class=" bibr popnode">36</a>]. Carbamidomethylation of cysteine was specified as a fixed modification, whereas oxidation (M), acetyl (protein N-term), and KGG (only for indicating SUMOylation) were defined as variable modifications. The false discovery rates (FDRs) of peptide and protein were set to 0.01 FDR.&#x02009;+&#x02009;2 as default charge state of each peptide. And at least one unique peptide of a protein successfully detected was considered to be acceptable.</p></div><div id="Sec11" class="sec"><h3 id="Sec11title">Xenograft tumor model</h3><p id="Par39" class="p p-first-last">All mouse experiments on BALB/c mice with 5-week-old were approved and conducted by the Institutional Animal Care and Treatment Committee of Sichuan University, China. A suspension containing 5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> HeLa or AnxA6-knockdown containing HeLa cells was subcutaneously injected into the right flanks of the 5-week-old male BALB/c nude mice (n&#x02009;=&#x02009;5) to construct tumor models respectively. Similarly, 5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells stably expressing Flag-AnxA6 or Flag-AnxA6<sup>K299R</sup> suspended in 100&#x000a0;&#x003bc;l PBS were harvested and injected into the right flanks of 5-week-old male BALB/c nude mice (<em>n</em>&#x02009;=&#x02009;5) individually. About 6&#x000a0;days after HeLa cell injection or 9&#x000a0;days after A431 cell injection, tumor volumes were measured every 3&#x000a0;days using a vernier caliper and calculated as follows: V&#x02009;=&#x02009;(length&#x02009;&#x000d7;&#x02009;width&#x02009;&#x000d7;&#x02009;height&#x02009;&#x000d7;&#x02009;0.5) mm<sup>3</sup>. At 30&#x000a0;days of inoculation, mice were sacrificed, and tumors were isolated, photographed, weighed and collected for further examination.</p></div><div id="Sec12" class="sec"><h3 id="Sec12title">Immunohistochemistry</h3><p id="Par40" class="p p-first-last">Immunohistochemistry (IHC) staining and quantitative scoring were performed as previously described [<a href="#CR37" rid="CR37" class=" bibr popnode">37</a>, <a href="#CR38" rid="CR38" class=" bibr popnode">38</a>]. The primary anti-Ki67 antibody was diluted at 1:800 to perform IHC, and all samples were visualized under a Leica DM 2000 microscope.</p></div><div id="Sec13" class="sec sec-last"><h3 id="Sec13title">Statistics analysis</h3><p id="Par41" class="p p-first-last">The significance of differences was determined using the Students test. All quantitative data were expressed as means&#x02009;&#x000b1;&#x02009;S.D. p&#x02009;&#x0003c;&#x02009;0.05 was regarded as a significant difference.</p></div></div><div id="Sec14" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec14title">Results</h2><div id="Sec15" class="sec sec-first"><h3 id="Sec15title">AnxA6 is modified by SUMO1 conjugation</h3><p id="Par42" class="p p-first">To determine which type of SUMO molecules conjugates with AnxA6, three kinds of exogenous His-tagging SUMO plasmids (pHis-SUMO1, pHis-SUMO2 and pHis-SUMO3) were simultaneously co-transfected with pFlag-AnxA6 and pHA-UBC9 plasmids into HEK293T cells to compare the SUMOylated AnxA6 levels. The Flag-tagging AnxA6 protein was captured from total cellular proteins by IP&#x000a0;using anti-Flag antibody beads. The most obvious SUMO-tagging AnxA6 bands with a molecular weight of 95&#x000a0;kDa (the expected normal size of AnxA6 is 75&#x000a0;kDa) appeared in cell co-transfection of pHis-SUMO1 and pHA-UBC9 plasmids (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>A, Lane 2). Similarly, we also transiently transfected pFlag-AnxA6 along with three kinds of exogenous His-tagging SUMO plasmids in HEK293T cells, and following the purification of His-tagging SUMO conjugates with Ni<sup>2+</sup>-NTA agarose beads. The most obvious SUMO-tagging AnxA6 band was also confirmed with anti-Flag antibody in the cells co-transfected with SUMO1, but not in the cells transfected with SUMO2 or SUMO3 (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>B, Lane 2). Taken together, our data indicated AnxA6 was obviously modified by SUMO1 conjugation.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig1" co-legend-rid="lgnd_Fig1"><a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614423474976"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig1_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig1_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig1_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614423474976"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig1"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1">Fig. 1</a></div><!--caption a7--><div class="caption"><p>The SUMOylated AnxA6 is detected under condition of protein overexpression. <strong>A</strong>-<strong>B</strong> The SUMOylated AnxA6 is mainly modified by SUMO1 in HEK293T cells. HEK293T cells were transiently co-transfected with pFlag-AnxA6, pHA-UBC9 and pHis-SUMO1(SUMO2/SUMO3) plasmids as indicated. Cells were collected at 48&#x000a0;h after transfection, and target proteins were captured by IP on anti-Flag antibody coupled agarose beads (<strong>A</strong>) or Ni<sup>2+</sup>-NTA agarose beads (<strong>B</strong>). Then the target protein was detected by immunoblotting with anti-Flag and anti-His antibodies. <strong>C</strong>-<strong>D</strong> The SUMOylation of AnxA6 was detected in response with UBC9/SUMO1 enhancement or inhibitor treatment (2-D08 or ML792). HEK293T cells were co-transiently transfected with pFlag-AnxA6 and pHA-UBC9 or pHis-SUMO1 plasmids as indicated. After transfection for 24&#x000a0;h, cells were treated with 150&#x000a0;&#x003bc;M 2-D08 (<strong>C</strong>) or 10&#x000a0;&#x003bc;M ML792 (<strong>D</strong>) for another 24&#x000a0;h. The Flag-tagging AnxA6 protein was enriched by IP on anti-Flag antibody coupled agarose beads (<strong>C</strong>) or Ni<sup>2+</sup>-NTA agarose beads (<strong>D</strong>), from which the SUMOylated AnxA6 level was analyzed through western blot using Flag or SUMO1 antibody. S-Flag-AnxA6: SUMOylated Flag-tagging AnxA6, IP: immunoprecipitation, IB: immunoblot, Input: Same account of cell lysate to load. 2-D08 or ML792: SUMOylation inhibitor</p></div></div></div><p id="Par43" class="p p-last">Next, we further detected AnxA6 SUMOylation change level in response with cell treatment by chemical SUMOylation inhibitors. The exogenous expressing AnxA6 protein was obviously SUMOylated by being transiently transfected pFlag-AnxA6 plasmids in HEK293T cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>C, Lane 2). As expected, the abundance of SUMOylated AnxA6 was significantly enhanced upon UBC9 stimulation (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>C, Lane 3). While under the treatment of 150&#x000a0;&#x003bc;M inhibitor 2-D08 for 24&#x000a0;h, SUMOylated AnxA6 was significantly decreased in spite of UBC9 existence (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>C, Lane 4), which was due to 2-D08 interference for the binding of UBC9 with SUMO1[<a href="#CR10" rid="CR10" class=" bibr popnode">10</a>]. In addition, we also observed AnxA6 SUMOylation was lost due to another SUMOylation inhibitor ML-792 treatment (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>D, Lane 4). Collectively, these data demonstrated that AnxA6 was modified with SUMO conjugation.</p></div><div id="Sec16" class="sec"><h3 id="Sec16title">K299 is a predominant SUMOylation site of AnxA6</h3><p id="Par44" class="p p-first">Next, the pFlag-AnxA6 and pHis-SUMO1<sup>T95K</sup> (T95 mutation to K) plasmids were simultaneously co-transfected into HEK293T cells to identify the AnxA6 SUMOyaltion site by MS/MS analysis. The obvious His-SUMO1<sup>T95K</sup>-tagging AnxA6 band was verified by Western blot against anti-His antibody (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>A). Using the mutant SUMO tagging method, K156, K299 and K314, which were non-consensus SUMOylation sites, were identified as potential predominant SUMOylation sites in AnxA6 by MS/MS analysis. The MS/MS spectra of the target peptides, including DAYERDLEADIIGDTSGHFQK<sup>156</sup>, YEK<sup>299</sup>SLYSMIK and NDTSGEYK<sup>314</sup>K of AnxA6, were obtained using HCD scan, which contained the SUMO-modified K156, K299 and K314 residue respectively (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>B). The matching parameters of MS/MS identification were summarized in Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>C.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig2" co-legend-rid="lgnd_Fig2"><a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614469886784"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig2_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig2_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig2_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614469886784"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig2"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2">Fig. 2</a></div><!--caption a7--><div class="caption"><p>K299 residue is one main SUMOylation site of AnxA6. <strong>A</strong> The SUMOylated AnxA6 was enriched and detected by His-SUMO1<sup>T95K</sup> tag. The His-SUMO1<sup>T95K</sup>-AnxA6 conjugated protein was enriched by IP on anti-Flag antibody coupled agarose beads, then the target protein was detected by immunoblotting with anti-Flag and anti-His antibodies. <strong>B-C</strong> MS/MS spectra of AnxA6 peptide DAYERDLEADIIGDTSGHFQK<sup>156</sup>, YEK<sup>299</sup>SLYSMIK, NDTSGEYK<sup>314</sup>K in HCD fragmentation mode. And the K156, K299, K314 were identified as the SUMOylation sites. <strong>D</strong> Several lysine residues of AnxA6 were predicted to be potential the consensus SUMOylation sites by a bioinformatics software analysis. <strong>E</strong>&#x02013;<strong>G</strong> Site mutant K299R significantly reduced SUMOylation level of AnxA6. HEK293T cells were co-transfected with plasmids pFlag-AnxA6, each of the single mutants, or pHis-SUMO1 as indicated. After 48&#x000a0;h later, cell lysates were performed IP to capture Flag-tagging AnxA6 (<strong>E</strong>) or His-tagging SUMO1 (<strong>F</strong>), which was immunoblotted with anti-SUMO1 antibody to show SUMOylation level. <strong>G</strong>&#x000a0;HEK293T cells were transfected with pFlag-AnxA6 or pFlag-AnxA6<sup>K299R</sup> plasmids along with pHis-SUMO1 to measure AnxA6 SUMOylation level. The levels of SUMOylation were determined as described in Methods. S-Flag-AnxA6: SUMOylated Flag-tagging AnxA6, IP: immunoprecipitation, IB: immunoblot, Input: same account of cell lysate to load</p></div></div></div><p id="Par45">As known, SUMOylation site within a protein typically occurs at the K residue that is located within the consensus sequence &#x003c8;KxD/E, where &#x0201c;&#x003c8;&#x0201d; is a hydrophobic residue and &#x0201c;x&#x0201d; means any sort of amino acid residue [<a href="#CR3" rid="CR3" class=" bibr popnode">3</a>]. Totally, four potential consensus SUMOylation sites including K75, K306, K418, and K579 of AnxA6 were predicted with high-ranking scores based on bioinformatics analysis using one online software GSP-SUMO (<a href="http://sumosp.biocuckoo.org/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://sumosp.biocuckoo.org/</a>) (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>D).</p><p id="Par46">To confirm the SUMOylation site on AnxA6, we constructed seven K-residue mutated plasmids, each with a single K point mutation, to validate SUMOylation level change of AnxA6.Compared with the other K-residue mutations including K75, K156, K306, K314, K418 and K579, the single site mutation of K299R greatly impaired AnxA6 SUMOylation level (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>E-Lane 7, 2F-Lane 8).</p><p id="Par47" class="p p-last">We further monitored SUMOylation level of the wild-type AnxA6 and the mutant AnxA6<sup>K299R</sup> under SUMO1 overexpression condition. Compared with the wild-type AnxA6 (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>G, Lane 2), the SUMOylation of AnxA6<sup>K299R</sup> mutant was most obviously reduced under co-transfecting with pSUMO1 plasmid in HEK293T cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2</span></a>G, Lane 4). Taken together, these findings indicated that K299 was a key SUMOylation site of AnxA6.</p></div><div id="Sec17" class="sec"><h3 id="Sec17title">AnxA6 SUMOylation inhibits EGFR/ERK pathway by stimulating PKC&#x003b1; binding to EGFR</h3><p id="Par48" class="p p-first">AnxA6 acts as a tumor suppressor through inhibiting EGFR/ERK pathway [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>, <a href="#CR24" rid="CR24" class=" bibr popnode">24</a>, <a href="#CR26" rid="CR26" class=" bibr popnode">26</a>], therefore we would explore whether SUMOylation of AnxA6 is involved in EGFR/ERK signaling regulation. As mentioned as Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span>1</span></a>B-D, the degree of AnxA6 SUMOylation was enhanced with the increase of UBC9 expression, while AnxA6 SUMOylation was decreased even lost under SUMOylation inhibitor ML-792 treatment. Thus, on the condition of loading equal amount of Flag-AnxA6, we compared changes of cellular EGFR/ERK signaling upon EGF stimulation under increasing UBC9 expression or ML792 inhibitor treatment.</p><p id="Par49">Cells were serum-starved for overnight and then stimulated with EGF for 5&#x000a0;min to detect EGFR/ERK signaling response. The pY-EGFR and p-ERK1/2 levels were further decreased even lost along with the co-transfection of pHA-UBC9 and Flag-AnxA6 plasmids (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>A, Lane 5), whereas AnxA6 deSUMOylation by the inhibitor ML792 treatment abolished its inhibition of EGFR/ERK phosphrylation under EGF stimulation (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>B, Lane 5). Meanwhile, the exogenous expression of wild-type AnxA6 (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>C-D, Lane 4), but not mutant AnxA6<sup>K299R</sup> (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>C-D, Lane 6), really inhibited pY-EGFR and p-ERK1/2 signaling compared to the endogenorus HeLa and A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>C-D, Lane 2).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig3" co-legend-rid="lgnd_Fig3"><a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614381671104"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig3_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig3_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig3_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614381671104"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig3"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3">Fig. 3</a></div><!--caption a7--><div class="caption"><p>AnxA6 SUMOylation inhibits EGFR/ERK pathway by promoting EGFR-PKC&#x003b1; interaction. <strong>A</strong>-<strong>B</strong> The UBC9 expression enhanced AnxA6-mediated inhibition of pY-EGFR and p-ERK1/2 levels, whereas the inhibitor ML792 treatment abolished suppression of EGFR/ERK phosphorylation due to AnxA6 upon EGF stimulation. HeLa or A431 cells were transfected with pFlag-AnxA6 plasmids for 24&#x000a0;h, followed to enhance or inhibit total SUMOylation by pHA-UBC9 plasmid transfection (<strong>A</strong>) or ML792 inhibitor incubation (<strong>B</strong>). Cells were serum-starved for overnight and then stimulated with 200&#x000a0;ng/ml (<strong>A</strong>) or 100&#x000a0;ng/ml&#x000a0;(<strong>B</strong>) EGF for 3&#x000a0;min, then cell lysates were harvested to detect protein expression of pY-EGFR, EGFR, pERK1/2, ERK1/2 and AnxA6. <strong>C-D</strong> The K299R mutation of AnxA6 impaired its ability to inactivate pY-EGFR and pERK1/2. HeLa (<strong>C</strong>) or A431 (<strong>D</strong>) cells were transfected with pFlag-AnxA6 or pFlag-AnxA6<sup>K299R</sup> plasmids for 36&#x000a0;h, starved overnight and followed with/without 100&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were immunoblotted with the indicated antibodies. <strong>E</strong> The K299R mutation impaired its recruitment ability of AnxA6 to promote EGFR-PKC&#x003b1; interaction. A431 cells were transfected with pFlag-AnxA6 or pFlag-AnxA6<sup>K299R</sup> plasmids for 36&#x000a0;h, starved overnight and followed with 100&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. One portion of cell lysates was performed IP to capture EGFR-binding complex, detected by western blot analysis with Flag, EGFR and PKC&#x003b1; antibodies. Another part of cell lysates was detected cellular protein level of Flag-AnxA6, EGFR and PKC&#x003b1;. <strong>F</strong> HeLa cells were co-transfected with the indicated plasmids for 24&#x000a0;h, followed ML792 treatment for 12&#x000a0;h, and cells were subjected to serum deprivation for overnight to stimulate with 100&#x000a0;ng/ml EGF for 3&#x000a0;min. One portion of cell lysates was performed IP to capture Flag-tagging AnxA6 binding protein complex, and detected protein expression by western blot analysis with Flag, SUMO1, EGFR and PKC&#x003b1; antibodies. Another part of cell lysates was detected cellular level of Flag-AnxA6, UbC9, SUMO1, EGFR and PKC&#x003b1;. <strong>G</strong> The K299R mutation of AnxA6 impaired its ability to interact EGFR but not affect its binding to PKC&#x003b1;. A431 cells were transfected with pFlag-AnxA6 or pFlag-AnxA6<sup>K299R</sup> plasmids for 36&#x000a0;h, starved overnight and followed with 100&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were immunoprecipitated to capture Flag-tagging AnxA6 and subsequently immunoblotted with indicated antibodies. S-Flag-AnxA6: SUMOylated Flag-tagging AnxA6, IP: immunoprecipitation, IB: immunoblot, Input: same account of cell lysate to load</p></div></div></div><p id="Par50">Our above results have proven the new concept that AnxA6 SUMOylation enhances its suppressive effect on EGFR/ERK phosphorylation in HeLa and A431 cells, so next we want to get insight into underlying the molecular mechanisms. Considering AnxA6 is a scaffold for promoting EGFR-PKC&#x003b1; interaction that is closely related with inactivation of EGFR/ERK pathway, we speculate that AnxA6 SUMOylation affects EGFR-PKC&#x003b1; complex formation. To validate the possibility, cell lysates were subjected to perform IP with EGFR antibody to enrich the EGFR-binding complex. The EGFR-binding PKC&#x003b1; was increased under EGF stimulation in AnxA6-overexpressing A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>E, Lane 4) compared with that of AnxA6<sup>K299R</sup>-overexpressing A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>E, Lane 6), which indicated that AnxA6 SUMOylation facilitated EGFR-PKC&#x003b1; complex formation. Interestingly, our data also showed that EGFR was susceptible to bind wild-type AnxA6 than mutant AnxA6<sup>K299R</sup> protein (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>E, Lanes 3&#x02013;4 versus Lane 5&#x02013;6), which supports AnxA6 SUMOylation enhances its binding with EGFR and subsequently promotes the association of PKC&#x003b1; with EGFR.</p><p id="Par51" class="p p-last">Indeed, we observed that an increased binding of AnxA6 with EGFR in HeLa cells correlated with an upregulation of AnxA6 SUMOylation level, whereas the binding of PKC&#x003b1; to AnxA6 was not changed under UBC9 overexpression or ML792 treatment (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>F, Lane 3&#x02013;4). To further validate this finding, we examined the effect of the K299 site mutant Flag-AnxA6<sup>K299R</sup> on the binding of EGFR and PKC&#x003b1;. Indeed, AnxA6 overexpression significantly enhanced the amount of EGFR that was enriched by IP against Flag-AxA6 antibody,&#x000a0;especially in the condition of EGF stimulation (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>G, Lane 3). In contrast, AnxA6<sup>K299R</sup> overexpression had no obvious effect on its interaction with EGFR in A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>G, Lane 6). Moreover, PKC&#x003b1; enriched by IP with Flag-AnxA6 antibody was a similar&#x000a0;amount&#x000a0;as to that bound with the Flag-AnxA6<sup>K299R</sup> (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span>3</span></a>G, Lanes 2&#x02013;3 versus 4&#x02013;5), which supported the conclusion that SUMOylation of AnxA6 did not mediate AnxA6-PKC&#x003b1; interaction. Collectively, these results indicate that AnxA6 SUMOylation promotes its binding with EGFR to increase EGFR-PKC&#x003b1; complex formation, thereby leading to inactivation of the EGFR/ERK phosphorylation signaling pathway.</p></div><div id="Sec18" class="sec"><h3 id="Sec18title">AnxA6 SUMOylation suppresses activation of EGFR&#x000a0;mutation-induced signal transduction</h3><p id="Par52" class="p p-first">EGFR&#x000a0;mutations (particularly&#x000a0;T790M&#x000a0;and&#x000a0;L858R&#x000a0;double mutation) are known as a major cause of EGFR signaling hyperactivation and EGFR-targeted drug acquired resistance in many cancers, especially in non-small cell lung carcinoma (NSCLC) [<a href="#CR39" rid="CR39" class=" bibr popnode">39</a>, <a href="#CR40" rid="CR40" class=" bibr popnode">40</a>]. We first investigated influence of EGFR mutation on AnxA6-mediated phosphorylation of EGFR and ERK1/2. We silenced the expression of AnxA6 in HeLa cells through the pLKO.1 lentiviral system with the specific AnxA6-targeting shRNA, and then transiently transfected pGFP-EGFR<sup>T790M/L858R</sup> plasmids into cells to generate a site double-mutated EGFR<sup>T790M/L858R</sup>. When AnxA6 expression was significant knockdown, the pY-GFP-EGFR<sup>T790M/L858R</sup>, pY-EGFR and p-ERK1/2 levels were further enhanced upon EGF stimulation (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>A), which indicated that AnxA6 also involved in EGFR mutation-induced signal transduction.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig4" co-legend-rid="lgnd_Fig4"><a href="/pmc/articles/PMC10391975/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614381456272"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig4_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig4_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig4_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614381456272"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig4"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4">Fig. 4</a></div><!--caption a7--><div class="caption"><p>AnxA6 SUMOylation inhibits activation of EGFR&#x000a0;mutation-induced signal transduction. <strong>A</strong> The the silencing of AnxA6 activate pY-GFP-EGFR<sup>T790M/L858R</sup> and pERK1/2. HeLa stable cells were generated by using lentiviral infections with indicated plasmids, and cells were transfected with pGFP-EGFR<sup>T790M/L858R</sup> plasmids for 24&#x000a0;h, starved overnight and followed with/without 10&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were immunoblotted with the indicated antibodies. <strong>B</strong> The K299R mutation of AnxA6 impaired its ability to inactivate pY-EGFR<sup>T790M/L858R</sup> and pERK1/2. A431 cells were co-transfected with the indicated plasmids for 24&#x000a0;h, starved overnight and followed with/without 10&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were immunoblotted with the indicated antibodies. <strong>C</strong> The K299R mutation impaired its recruitment ability of AnxA6 to promote GFP-EGFR<sup>T790M/L858R</sup>-PKC&#x003b1; interaction. A431 cells were co-transfected with the indicated plasmids for 24&#x000a0;h, starved overnight and followed with/without 10&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were IP to capture GFP-tagging EGFR<sup>T790M/L858R</sup> and subsequently immunoblotted with indicated antibodies. <strong>D</strong> The K299R mutation of AnxA6 impaired its ability to interact GFP-EGFR<sup>T790M/L858R</sup>. A431 cells were co-transfected with the indicated plasmids for 24&#x000a0;h, starved overnight and followed with/without 10&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were IP to capture Flag-tagging AnxA6 and subsequently immunoblotted with indicated antibodies. IP: immunoprecipitation, IB: immunoblot, Input: same account of cell lysate to load</p></div></div></div><p id="Par53">We further revealed whether AnxA6 SUMOylation had influence on mutant EGFR signal transduction. As shown in Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>B, the wild-type AnxA6 overexpression significantly suppressed the pY-GFP-EGFR<sup>T790M/L858R</sup>, pY-EGFR and p-ERK1/2 levels. In contrast, the mutant AnxA6<sup>K299R</sup> overexpression was unable to inhibit the phosphorylation levels of these proteins in A431 cells with transiently transfection of pGFP-EGFR<sup>T790M/L858R</sup> plasmids (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>B, Lanes 2 versus 4). Moreover, the GFP-EGFR<sup>T790M/L858R</sup>, as same as EGFR, increased its binding to PKC&#x003b1; and AnxA6 in AnxA6-expressing A431 cells upon EGF stimulation, but not in AnxA6<sup>K299R</sup>-expressing A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>C, Lane 2 versus 4).</p><p id="Par54" class="p p-last">Meanwhile, we enriched Flag-AnxA6<sup>K299R</sup>-binding protein complex by IP against Flag antibody and analyzed AnxA6<sup>K299R</sup>-binding EGFR level by Western blot. As expected, the wild-type AnxA6 exhibited an evidently increased binding capability with GFP-EGFR<sup>T790M/L858R</sup> than the mutant AnxA6<sup>K299R</sup> under EGF-treated conditions (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span>4</span></a>D, Lane 2 versus 3). Together, these data revealed that AnxA6 SUMOylation inhibited phosphorylation of EGFR<sup>T790M/L858R</sup>, thereby impeding EGFR&#x000a0;mutation-involved signal transduction.</p></div><div id="Sec19" class="sec"><h3 id="Sec19title">AnxA6 SUMOylation impedes cell proliferation and migration by inactivating pY-EGFR and p-ERK1/2</h3><p id="Par55" class="p p-first">Next, we clarified biological function of AnxA6 in cancer cell proliferation and migration. We first established AnxA6-knockdown cell model in HeLa by stably expressing shRNA targeting AnxA6, named HeLa-AnxA6(KD). Consistent with published data [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>], the pY-EGFR and p-ERK1/2 were significantly enhanced in HeLa-AnxA6(KD) cells after starvation following EGF stimulation (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>A, Lane 2 versus 4). And the AnxA6 knockdown also inhibited formation of EGFR-PKC&#x003b1; complex upon EGF stimulation (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>A, Lane 2 versus 4).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig5" co-legend-rid="lgnd_Fig5"><a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614423714864"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig5_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig5_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig5_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614423714864"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig5"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5">Fig. 5</a></div><!--caption a7--><div class="caption"><p>AnxA6 SUMOylation impedes cell proliferation and migration in EGFR-overexpressing cells by inactivating EGFR-ERK phosphorylation. <strong>A</strong> The the silencing of AnxA6 weakened the binding of PKC&#x003b1; with EGFR, thereby promoting the EGFR-ERK phosphorylation in HeLa cells. AnxA6-knockdown cell model in HeLa were generated by infecting with lentiviral expressing shRNA targeting to AnxA6, and cells were subjected to serum deprivation for overnight and followed with 100&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were IP to capture EGFR and subsequently immunoblotted with indicated antibodies. <strong>B-D</strong> AnxA6 knockdown promoted HeLa cell proliferation and migration.Cell proliferation (<strong>B-C</strong>) and migration (<strong>D</strong>) were respectively measured on HeLa cells and HeLa-AnxA6(KD) cells. Cells were grown in DEME media containing 0.1% (v/v) FBS and 100&#x000a0;ng/ml EGF. Representative colony formation images (left) and quantification of colonies (right) that compared with HeLa. Representative wound healing images (left) and the calculated cell migration distances (right). <strong>E</strong> The K299R mutation of AnxA6 impaired AnxA6 SUMOylation level, which weakened the binding of AnxA6 with EGFR and promoted the EGFR-ERK phosphorylation in A431 cells. A431 stable cells were generated by using lentiviral infections with indicated plasmids, and cells were subjected to serum deprivation for overnight and followed with 100&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. Cell lysates were IP to capture Flag-tagging AnxA6 and subsequently immunoblotted with indicated antibodies. <strong>F</strong>&#x02013;<strong>H</strong> The K299 mutation of AnxA6 impaired its suppression activity on A431 cell proliferation and migration. Cell proliferation <strong>(F</strong>-<strong>G)</strong> and cell migration <strong>(H)</strong> were respectively measured on A431 cells, A431-AnxA6 cells and A431-AnxA6<sup>K299R</sup> cells. Cells were grown in RPMI-1640 media containing 0.1% (v/v) FBS and 100&#x000a0;ng/ml EGF. Representative colony formation images (left) and quantification of colonies (right) that compared with A431. Representative wound healing images (left) and the calculated cell migration distances (right). <strong>I</strong>&#x000a0;The K299R mutation of AnxA6 impaired its activity in suppressing EGF-induced cyclin D1 expression. Cells (A431, A431-AnxA6, and A431-AnxA6<sup>K299R</sup>) were starved overnight and then treated with 100&#x000a0;ng/ml EGF for 0&#x02013;6&#x000a0;h as indicated. Ordinate value, relative cyclin D1 expression (fold of t min/0&#x000a0;min) means the ratio of cyclin D1 between t min and 0&#x000a0;min. Data were represented as the mean&#x02009;&#x000b1;&#x02009;SD of three separate experiments. *<em>p</em>&#x02009;&#x0003c;&#x02009;0.05;**<em>p</em>&#x02009;&#x0003c;&#x02009;0.01; ***<em>p</em>&#x02009;&#x0003c;&#x02009;0.001. S-Flag-AnxA6: SUMOylated Flag-tagging AnxA6, IP: immunoprecipitation, IB: immunoblot, Input: same account of cell lysate to load</p></div></div></div><p id="Par56">Moreover, the CCK8, colony-forming and wound healing assays were applied to detect AnxA6 knockdown-mediated cell proliferation and migration. In comparison with HeLa, cell growth and migration upon EGF induction were significantly promoted in HeLa-AnxA6(KD) cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>B-D).Taken together, these results indicated that AnxA6 impedes cell proliferation and migration in response to EGF stimulation by inactivating pY-EGFR and p-ERK1/2.</p><p id="Par57">We further tested AnxA6 SUMOylation influences on cell proliferation and migration. A431 stable cell lines were generated by using lentiviral infections with the Lenti-Vector carrying wild-type AnxA6 or mutant AnxA6<sup>K299R</sup> plasmid, and the corresponding two stable cell clones were named as A431-AnxA6 and A431-AnxA6<sup>K299R</sup>. Consistent with the above conclusions, the pY-EGFR and p-ERK1/2 in A431-AnxA6<sup>K299R</sup> cells were significantly increased than that of A431-AnxA6 cells upon EGF stimulation (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>E, Lanes 2 versus 3). Moreover, the level of AnxA6 SUMOylation and AnxA6-binding EGFR in A431-AnxA6<sup>K299R</sup> cells was much less than that in A431-AnxA6 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>E, Lanes 2 versus 3).</p><p id="Par58">In comparison with A431 cells, cell growth and migration upon EGF induction were lagged under the ectopic expression of wild-type AnxA6 and mutant AnxA6<sup>K299R</sup> in A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>F-H). It was noted cell proliferation and migration of A431-AnxA6<sup>K299R</sup> were relatively improved than A431-AnxA6 cells, which indicates SUMOylation of AnxA6 at K299 site is helpful to attenuate cell growth and migration.</p><p id="Par59" class="p p-last">To further confirm AnxA6 SUMOylation-mediated inhibition of the phosphorylation of EGFR/ERK signaling, we measured cell cycle regulator cyclin D1, a downstream target of EGFR/ERK signaling pathway (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>I). In A431 cells, upon with EGF stimulation, the cyclin D1 level was significantly increased from 0.5&#x000a0;h to 6&#x000a0;h (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>I, the top). By comparison, in the EGF-stimulated A431-AnxA6 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>I, the Middle), the increase degree of cyclin D1 was obviously slower within 2&#x000a0;h to 6&#x000a0;h than that of A431-AnxA6<sup>K299R</sup> cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span>5</span></a>I, the bottom). Thus, the K299R mutation of AnxA6 impaired its activity in suppressing EGF-induced cyclin D1 expression, which further illustrated that&#x000a0;AnxA6 SUMOylation inhibited phosphorylation of EGFR/ERK signaling transduction.</p></div><div id="Sec20" class="sec"><h3 id="Sec20title">AnxA6 SUMOylation improves gefitinib efficacy of suppressing A431 cell proliferation and migration</h3><p id="Par60" class="p p-first">We next evaluated whether AnxA6 co-operated with gefitinib to inhibit cancer cell proliferation and migration. HeLa and HeLa-AnxA6(KD) cells were incubated with 0-40&#x000a0;&#x000b5;M gefitinib for 48&#x000a0;h, then cell viability was determined by CCK8 assay. The difference in cell viability between HeLa and HeLa-AnxA6(KD) at 20&#x000a0;&#x003bc;M gefitinib incubation was the largest of all the concentrations (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>A). Under 20&#x000a0;&#x003bc;M gefitinib treatment, 77.1&#x02009;&#x000b1;&#x02009;5% HeLa-AnxA6(KD) cells kept cell viability, while 52.5&#x02009;&#x000b1;&#x02009;5% HeLa cells were alive (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>A). In addition, 20&#x000a0;&#x000b5;M gefitinib more effectively inhibited cell migration of HeLa cells compared to HeLa-AnxA6(KD) cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>C). These results indicated AnxA6 co-operated with gefitinib-mediated inhibition of cell growth and migration.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig6" co-legend-rid="lgnd_Fig6"><a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" rid-figpopup="Fig6" rid-ob="ob-Fig6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614381503456"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig6_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig6_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig6_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614381503456"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig6"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" rid-figpopup="Fig6" rid-ob="ob-Fig6">Fig. 6</a></div><!--caption a7--><div class="caption"><p>AnxA6 SUMOylation promotes gefitinib-mediated inhibition of epithelial cancer cell growth and migration. <strong>A-C</strong> AnxA6 knockdown impaired its ability of enhancing anti-proliferation and anti-migratory properties of gefitinib in HeLa cells. The CCK8 (<strong>A</strong>) and colony-forming (<strong>B</strong>) assays were used to measure cell proliferation ability of gefitinib-treated HeLa cells. Cells were grown in DMEM media containing 0.1% (v/v) FBS and 100&#x000a0;ng/ml EGF. Quantification of colonies was shown at right, which was calculated as the proportion of cell clone number relative to HeLa. <strong>C</strong> Cell motility was determined by wound healing assay in gefitinib-treated HeLa cells. The bar graphs showed cell migration distances, which were calculated relative to the initial distance before migration (right). <strong>D-F</strong> The K299 mutation of AnxA6 impaired its ability of enhancing anti-proliferation and anti-migratory properties of gefitinib in A431 cells. The CCK8 (<strong>D</strong>) and colony-forming (<strong>E</strong>) assays were used to measure cell proliferation ability of gefitinib-treated A431 cells. Cells were grown in RPMI-1640 media containing 0.1% (v/v) FBS and 100&#x000a0;ng/ml EGF. Quantification of colonies was shown at right, which was calculated as the proportion of cell clone number relative to A431. <strong>F</strong> Cell motility was determined by wound healing assay in gefitinib-treated A431 cells. The bar graphs showed cell migration distances, which were calculated relative to the initial distance before migration (right). <strong>G</strong> The K299 mutation of AnxA6 impaired its ability of enhancing gefitinib-mediated inhibition of EGFR-ERK signaling. The A431, A431-AnxA6, and A431-AnxA6<sup>K299R</sup> cells were treated with 10&#x000a0;&#x003bc;M gefitinib for 24&#x000a0;h, and followed with 100&#x000a0;ng/ml EGF treatment for 3&#x000a0;min. The levels of pY-EGFR, EGFR, pERK1/2, ERK1/2 and AnxA6 were determined by western blotting. Data were represented as the mean&#x02009;&#x000b1;&#x02009;SD of three separate experiments. ns, no statistical; *<em>p</em>&#x02009;&#x0003c;&#x02009;0.05;**<em>p</em>&#x02009;&#x0003c;&#x02009;0.01; ***<em>p</em>&#x02009;&#x0003c;&#x02009;0.001</p></div></div></div><p id="Par61">Considering AnxA6 improving anti-growth and anti-migratory effect of gefitinib, we speculated that AnxA6 SUMOylation enhanced gefitinib efficacy to reduce epithelial cancer cell proliferation and migration. Similarly, A431, A431-AnxA6 and A431-AnxA6<sup>K299R</sup> cells were incubated with 0-30&#x000a0;&#x000b5;M gefitinib for 24&#x000a0;h to allow cell proliferation, and cell viability was determined by CCK8 assays. The difference in cell viability between A431-AnxA6 and A431-AnxA6<sup>K299R</sup> at 10&#x000a0;&#x003bc;M gefitinib was the largest of all the concentrations (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>D). Under 10&#x000a0;&#x003bc;M gefitinib treatment, 65.1&#x02009;&#x000b1;&#x02009;5% A431-AnxA6<sup>K299R</sup> cells kept cell viability, while 55.1&#x02009;&#x000b1;&#x02009;5% A431-AnxA6 cells were alive (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>D). In addition, 2.5 or 5&#x000a0;&#x003bc;M gefitinib led to less colony formation in A431-AnxA6 cells compared to A431-AnxA6<sup>K299R</sup> cells or A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>E).</p><p id="Par62">Moreover, the wound healing assays also shown that gefitinib more effectively inhibited A431-AnxA6 cell migration compared to A431-AnxA6<sup>K299R</sup> cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>F). These results suggested that AnxA6 SUMOylation enhanced the efficacy of gefitinib to reduce squamous epithelial cancer cell proliferation and migration.</p><p id="Par63" class="p p-last">We further investigated EGFR/ERK signaling changes between A431-AnxA6 and A431-AnxA6<sup>K299R</sup> cells with 0-10&#x000a0;&#x000b5;M gefitinib treatment for 24&#x000a0;h. The pY-EGFR and p-ERK1/2 in A431-AnxA6 cells were significantly reduced than the A431-AnxA6<sup>K299R</sup> cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6</span></a>G), which further demonstrated that AnxA6 SUMOylation cooperated with gefitinib to inhibit EGFR/ERK phosphorylation signaling.</p></div><div id="Sec21" class="sec sec-last"><h3 id="Sec21title">AnxA6 SUMOylation inhibits tumor growth of nude mouse model</h3><p id="Par64" class="p p-first">Finally, we evaluated AnxA6 anti-tumor effect in xenograft nude mouse model. 5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> HeLa cells or HeLa-AnxA6(KD) cells were inoculated into the right flank of nude mice. About 6&#x000a0;days after injection, the tumors in each group were obviously palpable with 50 mm<sup>3</sup>, and subsequently the tumor size was totally monitored for 6 times from then on. At 21&#x000a0;days of inoculation, AnxA6 knockdown in HeLa cells significantly promoted tumorigenesis (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>A) and tumor growth (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>B). A larger tumor volume with 435.1&#x02009;&#x000b1;&#x02009;185.6mm<sup>3</sup> (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>B) and tumor weight with 0.22&#x02009;&#x000b1;&#x02009;0.08&#x000a0;g (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>C) was respectively observed in HeLa-AnxA6(KD)-injected mouse than HeLa-xenografted tumor with 204.0&#x02009;&#x000b1;&#x02009;63.9mm<sup>3</sup> volume and 0.09&#x02009;&#x000b1;&#x02009;0.03&#x000a0;g weight. In addition, compared with the HeLa-AnxA6(KD) derived tumors, levels of pY-EGFR and p-ERK1/2 in HeLa- xenografted tumors were reduced (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>D).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig7" co-legend-rid="lgnd_Fig7"><a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" rid-figpopup="Fig7" rid-ob="ob-Fig7"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614434945312"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig7_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig7_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig7_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614434945312"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig7/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig7"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" rid-figpopup="Fig7" rid-ob="ob-Fig7">Fig. 7</a></div><!--caption a7--><div class="caption"><p>AnxA6 SUMOylation inhibits tumor growth of the epithelial cancer cells-xenografted nude mouse model. <strong>A</strong>-<strong>D</strong> AnxA6 knockdown promotes tumor growth in HeLa-xenografted mice. <strong>A-C</strong> 5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells, including HeLa and HeLa-AnxA6(KD), were injected subcutaneously into male BALB/c nude mice (<em>n</em>&#x02009;=&#x02009;5) individually (<strong>A</strong>). The sizes of tumors were measured at day 6, 9, 12, 15, 18 and 21 after injection (<strong>B</strong>), and the tumors were weighed (<strong>C</strong>). And the expression of pY-EGFR, EGFR, pERK1/2, ERK1/2 and AnxA6 were analyzed in HeLa and HeLa-AnxA6(KD)-xenografted tumors&#x000a0;(<strong>D</strong>). <strong>E</strong>&#x02013;<strong>G</strong> The K299 mutation of AnxA6 impaired its cancer suppression effection on A431-xenograft tumor growth. 5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells, including A431, A431-AnxA6, and A431-AnxA6<sup>K299R</sup>, were injected subcutaneously into male BALB/c nude mice (<em>n</em>&#x02009;=&#x02009;5) individually (<strong>E</strong>). The sizes of tumors were measured at day 9, 12, 15, 18, 21, 24, 27 and 30 after injection (<strong>F</strong>), and the tumors were weighed (<strong>G</strong><strong>)</strong>. <strong>H</strong> Ki-67 expression was detected by immunohistochemical staining in A431-xenograft tumors at 30&#x000a0;days after implantation (50&#x02009;&#x000d7;) (left), and the rates of staining positivity for Ki-67 were shown at right. <strong>I</strong> The K299R mutation of AnxA6 impaired its ability to inactivate the pY-EGFR and pERK1/2 in A431-xenograft tumors. The expression of pY-EGFR, EGFR, pERK1/2, ERK1/2 and AnxA6 were analyzed in A431, A431-AnxA6, and A431-AnxA6.<sup>K299R</sup>-xenografted tumors.T1-T5: tumor tissues from HeLa-xenograft nude mouse.T1-T3: tumor tissues from A431-xenograft nude mouse. *<em>p</em>&#x02009;&#x0003c;&#x02009;0.05;**<em>p</em>&#x02009;&#x0003c;&#x02009;0.01</p></div></div></div><p id="Par65">Similarly, AnxA6 SUMOyaltion-inhibited epithelial cancer development and molecular events were further confirmed in A431-xenograft mice. We subcutaneously injected A431 cells, which stably expressing either AnxA6 or AnxA6<sup>K299R</sup>, into BABL/c mice to observe tumor growth. About 9&#x000a0;days after injection, the tumors in each group were obviously palpable with 100mm<sup>3</sup>, and subsequently the tumor size was totally monitored for 8 times from then on.</p><p id="Par66">At 30&#x000a0;days of inoculation, we observed that both the wild type AnxA6 and mutant AnxA6<sup>K299R</sup> dramatically inhibited the subcutaneous growth of A431 cells (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>E-G). However, the A431-AnxA6<sup>K299R</sup> derived tumor, with 613.8&#x02009;&#x000b1;&#x02009;113.8mm<sup>3</sup> and 0.31&#x02009;&#x000b1;&#x02009;0.065&#x000a0;g, was much greater than the A431-AnxA6 inoculated tumor with 324.9&#x02009;&#x000b1;&#x02009;107mm<sup>3</sup> and 0.15&#x02009;&#x000b1;&#x02009;0.06&#x000a0;g (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>F-G). In addition, the A431-AnxA6 derived tumors exhibited Ki67 downregulation that the A431-AnxA6<sup>K299R</sup> xenografted tumors (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>H).</p><p id="Par67" class="p p-last">Moreover, we also validated EGFR/ERK signaling changes between AnxA6 and AnxA6<sup>K299R</sup>-expressing tumor tissues from A431-xenograft nude mice. Compared with the A431-AnxA6<sup>K299R</sup> tumors, levels of pY-EGFR and p-ERK1/2 in the A431-AnxA6 tumors were reduced (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig7/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig7" rid-ob="ob-Fig7" co-legend-rid="lgnd_Fig7"><span>7</span></a>I), and the conclusion was consistent with the data in vitro. Together, there data indicated SUMOylation-deficient AnxA6 had lost tumor-suppressor activity in vivo.</p></div></div><div id="Sec22" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec22title">Discussion</h2><p id="Par68" class="p p-first">AnxA6 is a member of a conserved superfamily of Ca<sup>2+</sup>-dependent membrane-binding annexin proteins to play multiple biochemical functions. The expression levels of AnxA6 are closely associated with melanoma, cervical cancer, epithelial carcinoma, breast cancer, gastric cancer, prostate cancer, acute lymphoblastic leukemia, chronic myeloid leukemia, large-cell lymphoma, and myeloma [<a href="#CR41" rid="CR41" class=" bibr popnode">41</a>, <a href="#CR42" rid="CR42" class=" bibr popnode">42</a>]. And AnxA6 is also a potential candidate target for antibody-mediated inhibition of cancer [<a href="#CR43" rid="CR43" class=" bibr popnode">43</a>]. Numerous previous studies have focused on AnxA6 biological function by manipulating protein levels using knockout or knock-in methods. However, the PTMs of AnxA6 are rarely reported. In current study, we have identified AnxA6 SUMOylation with the K299 residue by MS/MS through introducing a T95K point mutation into the C-terminus of SUMO1 to facilitate catching SUMOylayted peptides [<a href="#CR44" rid="CR44" class=" bibr popnode">44</a>]. The T95K mutant SUMO tagging method does not affect the function of SUMO-1, but generates a new cutting site that leaves a Gly-Gly signature on the SUMOylated peptides after Lys-C digestion [<a href="#CR44" rid="CR44" class=" bibr popnode">44</a>]. This is an efficient MS identification method for SUMOylation site.</p><p id="Par69">SUMO is a highly conserved molecule to conjugate to the K residue of a substrate protein in the PTM process. Numerous studies indicate that SUMOylation attenuates or escalates biological activities of the substrate protein [<a href="#CR7" rid="CR7" class=" bibr popnode">7</a>, <a href="#CR45" rid="CR45" class=" bibr popnode">45</a>&#x02013;<a href="#CR47" rid="CR47" class=" bibr popnode">47</a>], which is dependent on specific conditions including disease types, the interacting partners with the substrate protein, and the protein complex-regulated signal pathway. For instance, large tumor suppressor 1, the core to mediate Hippo growth-inhibitory signaling pathway, is found to be modified by SUMO1 at K751 residue and attenuates its kinase activity and tumor-suppressor functions [<a href="#CR46" rid="CR46" class=" bibr popnode">46</a>]. Conversely, the adaptor protein Grb2 is SUMOylated by SUMO1 at K56, which increases the formation of Grb2-Sos1 complex and subsequently enhances its oncogene functions [<a href="#CR47" rid="CR47" class=" bibr popnode">47</a>]. In this study, our results support that AnxA6 SUMOylation at K299 residue facilitates the binding of PKC&#x003b1; to EGFR and subsequently enhances its tumor-suppressor activity in vitro and in vivo (Fig.&#x000a0;<a href="/pmc/articles/PMC10391975/figure/Fig8/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig8" rid-ob="ob-Fig8" co-legend-rid="lgnd_Fig8"><span>8</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="Fig8" co-legend-rid="lgnd_Fig8"><a href="/pmc/articles/PMC10391975/figure/Fig8/" target="figure" rid-figpopup="Fig8" rid-ob="ob-Fig8"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140614471761792"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10391975_12964_2023_1217_Fig8_HTML.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Fig8_HTML.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Fig8_HTML.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140614471761792"><a target="object" rel="noopener" href="/pmc/articles/PMC10391975/figure/Fig8/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig8"><div><a class="figpopup" href="/pmc/articles/PMC10391975/figure/Fig8/" target="figure" rid-figpopup="Fig8" rid-ob="ob-Fig8">Fig. 8</a></div><!--caption a7--><div class="caption"><p>A working mechanism model of AnxA6&#x000a0;roles in EGFR-expressing epithelial cancer cells. Comparison with the AnxA6 (left) in the un-stimulated cells, the SUMOylated AnxA6 with K299 SUMO1 conjugation (right) is prone to bind EGFR in response to EGF, which facilitates EGFR-PKC&#x003b1; complex formation to decrease the EGF-induced phosphorylation of EGFR-ERK1/2 and cyclin D1 expression, and finally contributes to the stronger inhibition of cell proliferation, migration and tumor growth in the epithelial cancer cells-xenografted nude mouse model, as well as improves gefitinib drug sensitivity
<img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Figa_HTML.gif" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Figa_HTML.gif" />
, 
<img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Figb_HTML.gif" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Figb_HTML.gif" />
,
<img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12964_2023_1217_Figc_HTML.gif" src="/pmc/articles/PMC10391975/bin/12964_2023_1217_Figc_HTML.gif" />
.</p></div></div></div><p id="Par70">The endogenous AnxA6 is absent in EGFR-overexpressing A431 cells, while a high level of AnxA6 is detectable in HeLa cells with moderate expression of EGFR [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>, <a href="#CR42" rid="CR42" class=" bibr popnode">42</a>]. And A431 cell belong to a model cells derived from squamous cell epithelia that retain the basic characteristics of the transformed phenotype [<a href="#CR42" rid="CR42" class=" bibr popnode">42</a>], therefore these cells are a well-recognized model for studying action mechanism of AnxA6 regulation on EGFR activity and the testing of pharmacological drugs targeting EGFR [<a href="#CR14" rid="CR14" class=" bibr popnode">14</a>, <a href="#CR23" rid="CR23" class=" bibr popnode">23</a>&#x02013;<a href="#CR26" rid="CR26" class=" bibr popnode">26</a>]. Several previous reports uncover the scaffolding/targeting function of AnxA6 for the PKC&#x003b1; [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>, <a href="#CR26" rid="CR26" class=" bibr popnode">26</a>], both negative regulators of the EGFR-ERK pathway, probably contributes to reduce proliferation/migration of epithelial cancer cells [<a href="#CR14" rid="CR14" class=" bibr popnode">14</a>, <a href="#CR23" rid="CR23" class=" bibr popnode">23</a>, <a href="#CR24" rid="CR24" class=" bibr popnode">24</a>, <a href="#CR26" rid="CR26" class=" bibr popnode">26</a>]. And the cyclin D1, a downstream target molecule of EGFR-ERK pathway, is inhibited due to AnxA6 overexpression in EGF-induced A431 cells [<a href="#CR23" rid="CR23" class=" bibr popnode">23</a>, <a href="#CR24" rid="CR24" class=" bibr popnode">24</a>]. Consistently, our study shows that overexpression of Flag-AnxA6, but not the SUMO-deficient mutant Flag-AnxA6<sup>K299R</sup> or control pFlag vector, the most markedly suppresses cell proliferation, migration and reduced cyclin D1 expression in the A431 cells with EGF stimulation. Noticeably, the pY-EGFR and p-ERK1/2 are significantly reduced in AnxA6 wild type cells compared with AnxA6<sup>K299R</sup> mutant cells. But the mutant AnxA6<sup>K299R</sup> still have effective inhibition of pY-EGFR and p-ERK1/2, which suggests that other AnxA6 SUMOylation sites might be involved in the regulation of this pathway. Moreover, it's worth noting that Ca<sup>2+</sup> is necessary for AnxA6 activation [<a href="#CR14" rid="CR14" class=" bibr popnode">14</a>, <a href="#CR23" rid="CR23" class=" bibr popnode">23</a>, <a href="#CR24" rid="CR24" class=" bibr popnode">24</a>, <a href="#CR26" rid="CR26" class=" bibr popnode">26</a>]. The cytosolic AnxA6 constitutively binds to PKC&#x003b1; in physiological state, while EGF stimulation increases intracellular Ca<sup>2+</sup>, which promotes the AnxA6-induced membrane recruitment of PKC&#x003b1; to EGFR in A431 cells [<a href="#CR24" rid="CR24" class=" bibr popnode">24</a>, <a href="#CR26" rid="CR26" class=" bibr popnode">26</a>, <a href="#CR41" rid="CR41" class=" bibr popnode">41</a>]. In this study, we discover that the formation of EGFR-PKC&#x003b1; complex is finely regulated by SUMO1 modification at K299 of AnxA6. In particular, our results reveal that the SUMO1 modification of AnxA6 facilitates AnxA6 binding with EGFR other than PKC&#x003b1;, ultimately attributing to the formation of EGFR-PKC&#x003b1; complex in response to extra-cellular EGF stimulation.</p><p id="Par71">In addition to gene amplification of EGFR, activating&#x000a0;mutations from EGFR are also one of the most common targetable oncogenic drivers in multiple cancers. The exon 19 deletions and L858R&#x000a0;mutations&#x000a0;are known as "classical"&#x000a0;mutations, account for 85&#x02013;90% of the total&#x000a0;EGFR mutations, whereas approximately 10% of patients have uncommon&#x000a0;EGFR&#x000a0;mutations including S768I, T790M, C797S and L861Q codons, and exon 20 insertions [<a href="#CR48" rid="CR48" class=" bibr popnode">48</a>&#x02013;<a href="#CR51" rid="CR51" class=" bibr popnode">51</a>]. And mutations in the EGFR, especially the T790M/L858R double mutation, have made cancer treatment more difficult [<a href="#CR51" rid="CR51" class=" bibr popnode">51</a>]. In this study, our results show that AnxA6 knockdown or K299 mutation of AnxA6 upregulates the phosphorylation level of exogenous expressing EGFR<sup>T790M/L858R</sup> in HeLa and A431 cells, which implicates AnxA6, especially AnxA6 SUMOylation exerts inhibiting phosphorylation signaling from EGFR&#x000a0;and mutant EGFR.</p><p id="Par72">So far, the EGFR inhibition has been established a major therapeutic target in cancer therapy, particularly for tumors of breast, cervix, ovaries, kidney, esophagus, prostate and NSCLC [<a href="#CR15" rid="CR15" class=" bibr popnode">15</a>&#x02013;<a href="#CR18" rid="CR18" class=" bibr popnode">18</a>]. EGFR-TKIs, such as gefitinib, erlotinib, afatinib, dacomitinib and osimertinib, have improved the outcomes of EGFR-dependent cancers for many patients [<a href="#CR52" rid="CR52" class=" bibr popnode">52</a>]. However, patients eventually experience the rapid acquisition of resistance due to various mechanisms, such as compensatory activation of signaling effectors downstream of EGFR and other growth factor receptors and secondary mutations in EGFR [<a href="#CR53" rid="CR53" class=" bibr popnode">53</a>]. Thus, identifying an efficient therapeutic target to restore gefitinib sensitivity and improve tumor control in patients is an urgent need. Several recent studies have revealed that AnxA6 regulated the subcellular location of PKC&#x003b1;, with consequences not only for the activity, but also the localization and trafficking of PKC&#x003b1; interaction partners, including EGFR, which could ultimately also affect susceptibility for drugs targeting the EGFR-TKI domain [<a href="#CR14" rid="CR14" class=" bibr popnode">14</a>, <a href="#CR54" rid="CR54" class=" bibr popnode">54</a>]. Indeed, our findings partly support this conclusion that AnxA6 SUMOylation enhances gefitinib efficacy to reduce A431 cell growth and migration, which indicates that AnxA6 SUMOylation may be an underlying novel mechanism for the EGFR-TKI resistance in many cancers.</p><p id="Par73" class="p p-last">Generally, we have revealed a previously unreported PTM form and molecular mechanism of AnxA6 SUMOylation in enhancing EGFR-PKC&#x003b1; complex formation to suppress phosphorylation of EGFR-ERK1/2 signaling pathway, which more effectively enables gefitinib to inhibit proliferation and migration of EGFR-overexpressing epithelial cancer cells.</p></div><div id="Sec23" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec23title">Conclusions</h2><p id="Par74" class="p p-first-last">In conclusion, we have revealed the modification of AnxA6 by SUMO1 conjugation to escalate its functions especially involving in dephosphorylation of EGFR-ERK1/2 signaling, and AnxA6 SUMOylation at K299 residue facilitates the binding of PKC&#x003b1; to EGFR and subsequently impedes EGFR activity, thereby inhibiting cell proliferation, migration, and the xenograft tumor growth of epithelial cancer cells, as well as improving gefitinib drug sensitivity. Moreover, AnxA6 SUMOylation can also inhibit the activating&#x000a0;EGFR&#x000a0;mutations signal transduction. Together, our novel findings indicate besides EGFR gene mutation, PTM&#x000a0;of the EGFR-binding protein AnxA6 also functions pivotal roles in&#x000a0;mediating cancer cell growth and EGFR inhibitor drug effect.</p></div><div id="sec-a.q.f" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="sec-a.q.ftitle">Supplementary Information</h2><!--/article/body/sec/--><div id="Sec1800" class="sec sec-first-last"><p class="p p-first-last">
</p><div class="sec suppmat" id="MOESM1"><div class="sup-box half_rhythm" id="media-a.q.f.b.a.a.a"><a href="/pmc/articles/PMC10391975/bin/12964_2023_1217_MOESM1_ESM.zip" data-ga-action="click_feat_suppl"><strong>Additional file 1</strong>.</a><sup>(272M, zip)</sup></div></div><p></p></div></div><div id="ack-a.r.c" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.r.ctitle">Acknowledgements</h2><div class="sec"><p>Not applicable.</p></div></div><div id="glossary-a.r.a" class="tsec sec"><h2 class="head no_bottom_margin" id="glossary-a.r.atitle">Abbreviations</h2><div class="bk-sec"><div><table class="default-table glossary"><tbody><tr><td>WB</td><td>Western blot</td></tr><tr><td>PTMs</td><td>Post-translational modifications</td></tr><tr><td>SUMO</td><td>The small ubiquitin-like modifier</td></tr><tr><td>K</td><td>Lysine</td></tr><tr><td>R</td><td>Arginine</td></tr><tr><td>AnxA6</td><td>Annexin A6</td></tr><tr><td>EGFR</td><td>Epidermal growth factor receptor</td></tr><tr><td>ERK)1/2</td><td>Extracellular-signal-regulated kinase</td></tr><tr><td>EGF</td><td>Epidermal growth factor</td></tr><tr><td>pY-EGFR</td><td>Tyrosine phosphorylation of epidermal growth factor receptor</td></tr><tr><td>NSCLC</td><td>Non-small cell lung carcinoma</td></tr><tr><td>TKIs</td><td>Tyrosine kinase inhibitors</td></tr><tr><td>p-ERK1/2</td><td>Phosphorylation of extracellular-signal-regulated kinases ERK1/2</td></tr><tr><td>IP</td><td>Immunoprecipitation</td></tr><tr><td>FBS</td><td>Fetal bovine serum</td></tr><tr><td>HCD</td><td>Higher-energy collisional dissociation</td></tr><tr><td>PKC&#x003b1;&#x000a0;</td><td>Protein kinase C&#x003b1; </td></tr><tr><td>IHC</td><td>Immunohistochemistry</td></tr></tbody></table></div></div></div><div id="notes-a.r.d" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.dtitle">Authors&#x02019; contributions</h2><p>SZ carried out experiments and wrote the manuscript draft.&#x000a0;CX performed experiments.&#x000a0;DY and ZX analyzed MS data. LS supervised the study, instructed experiments and revised manuscript. All authors participated in the preparation of the manuscript, read and approved the final manuscript.</p></div><div id="notes-a.r.e" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.etitle">Funding</h2><p>This work was supported by the National Natural Science Foundation of China (31961143005, 31470810), and Foundation of Chengdu Science &#x00026; Technology Committee (2020-GH03-00004-HZ)<em>.</em></p></div><div id="notes-a.r.f" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.ftitle">Availability of data and materials</h2><p>The MS proteomics data and the search data by MaxQuant is available in the Mendeley Data (<a href="https://data.mendeley.com/datasets/rdw3fk6cng/1" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://data.mendeley.com/datasets/rdw3fk6cng/1</a>).</p></div><div id="notes-a.r.g" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.gtitle">Declarations</h2><div>Ethics approval and consent to participate<p id="Par75">The animal study were performed in accordance with the guidelines of Sichuan University and approved by the Animal Care Committee of Sichuan University (Chengdu, China).</p></div><div>Consent for publication<p id="Par76">Not applicable.</p></div><div>Competing interests<p id="Par77">The authors declare no competing interests.</p></div></div><div id="fn-group-a.r.b" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.r.btitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.r.b.a"><p class="p p-first"><strong>Publisher&#x02019;s Note</strong></p><p class="p p-last">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></p></div></div><div id="Bib1" class="tsec sec"><h2 class="head no_bottom_margin" id="Bib1title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="CR1">1. <span class="element-citation">Sheng Z, Zhu J, Deng YN, Gao S, Liang S. SUMOylation modification-mediated cell death. <span><span class="ref-journal">Open Biol. </span>2021;<span class="ref-vol">11</span>:210050. doi: 10.1098/rsob.210050.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8277462/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34255975" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1098%2Frsob.210050" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Open+Biol&amp;title=SUMOylation+modification-mediated+cell+death&amp;author=Z+Sheng&amp;author=J+Zhu&amp;author=YN+Deng&amp;author=S+Gao&amp;author=S+Liang&amp;volume=11&amp;publication_year=2021&amp;pages=210050&amp;pmid=34255975&amp;doi=10.1098/rsob.210050&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR2">2. <span class="element-citation">Du L, Liu W, Rosen ST. Targeting SUMOylation in cancer. <span><span class="ref-journal">Curr Opin Oncol. </span>2021;<span class="ref-vol">33</span>:520–525. doi: 10.1097/CCO.0000000000000765.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34280172" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1097%2FCCO.0000000000000765" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Oncol&amp;title=Targeting+SUMOylation+in+cancer&amp;author=L+Du&amp;author=W+Liu&amp;author=ST+Rosen&amp;volume=33&amp;publication_year=2021&amp;pages=520-525&amp;pmid=34280172&amp;doi=10.1097/CCO.0000000000000765&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR3">3. <span class="element-citation">Yang Y, He Y, Wang X, Liang Z, He G, Zhang P, et al. Protein SUMOylation modification and its associations with disease. <span><span class="ref-journal">Open Biol. </span>2017;<span class="ref-vol">7</span>:170167. doi: 10.1098/rsob.170167.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5666083/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29021212" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1098%2Frsob.170167" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Open+Biol&amp;title=Protein+SUMOylation+modification+and+its+associations+with+disease&amp;author=Y+Yang&amp;author=Y+He&amp;author=X+Wang&amp;author=Z+Liang&amp;author=G+He&amp;volume=7&amp;publication_year=2017&amp;pages=170167&amp;pmid=29021212&amp;doi=10.1098/rsob.170167&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR4">4. <span class="element-citation">Zhu X, Qiu C, Wang Y, Jiang Y, Chen Y, Fan L, et al. FGFR1 SUMOylation coordinates endothelial angiogenic signaling in angiogenesis. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2022;<span class="ref-vol">119</span>:e2202631119. doi: 10.1073/pnas.2202631119.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9245619/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35733256" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.2202631119" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=FGFR1+SUMOylation+coordinates+endothelial+angiogenic+signaling+in+angiogenesis&amp;author=X+Zhu&amp;author=C+Qiu&amp;author=Y+Wang&amp;author=Y+Jiang&amp;author=Y+Chen&amp;volume=119&amp;publication_year=2022&amp;pages=e2202631119&amp;pmid=35733256&amp;doi=10.1073/pnas.2202631119&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR5">5. <span class="element-citation">Dai X, Zhang T, Hua D. Ubiquitination and SUMOylation: protein homeostasis control over cancer. <span><span class="ref-journal">Epigenomics. </span>2022;<span class="ref-vol">14</span>:43–58. doi: 10.2217/epi-2021-0371.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34875856" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2217%2Fepi-2021-0371" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epigenomics&amp;title=Ubiquitination+and+SUMOylation:+protein+homeostasis+control+over+cancer&amp;author=X+Dai&amp;author=T+Zhang&amp;author=D+Hua&amp;volume=14&amp;publication_year=2022&amp;pages=43-58&amp;pmid=34875856&amp;doi=10.2217/epi-2021-0371&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR6">6. <span class="element-citation">Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, et al. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. <span><span class="ref-journal">Nat Commun. </span>2021;<span class="ref-vol">12</span>:1812. doi: 10.1038/s41467-021-22163-7.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7985146/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33753739" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41467-021-22163-7" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=SUMOylation+controls+the+binding+of+hexokinase+2+to+mitochondria+and+protects+against+prostate+cancer+tumorigenesis&amp;author=X+Shangguan&amp;author=J+He&amp;author=Z+Ma&amp;author=W+Zhang&amp;author=Y+Ji&amp;volume=12&amp;publication_year=2021&amp;pages=1812&amp;pmid=33753739&amp;doi=10.1038/s41467-021-22163-7&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR7">7. <span class="element-citation">Liang Z, Yang Y, He Y, Yang P, Wang X, He G, et al. SUMOylation of IQGAP1 promotes the development of colorectal cancer. <span><span class="ref-journal">Cancer Lett. </span>2017;<span class="ref-vol">411</span>:90–99. doi: 10.1016/j.canlet.2017.09.046.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28987385" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.canlet.2017.09.046" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Lett&amp;title=SUMOylation+of+IQGAP1+promotes+the+development+of+colorectal+cancer&amp;author=Z+Liang&amp;author=Y+Yang&amp;author=Y+He&amp;author=P+Yang&amp;author=X+Wang&amp;volume=411&amp;publication_year=2017&amp;pages=90-99&amp;pmid=28987385&amp;doi=10.1016/j.canlet.2017.09.046&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR8">8. <span class="element-citation">Rao HB, Qiao H, Bhatt SK, Bailey LR, Tran HD, Bourne SL, et al. A SUMO-ubiquitin relay recruits proteasomes to chromosome axes to regulate meiotic recombination. <span><span class="ref-journal">Science. </span>2017;<span class="ref-vol">355</span>:403–407. doi: 10.1126/science.aaf6407.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5569317/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28059716" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.aaf6407" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=A+SUMO-ubiquitin+relay+recruits+proteasomes+to+chromosome+axes+to+regulate+meiotic+recombination&amp;author=HB+Rao&amp;author=H+Qiao&amp;author=SK+Bhatt&amp;author=LR+Bailey&amp;author=HD+Tran&amp;volume=355&amp;publication_year=2017&amp;pages=403-407&amp;pmid=28059716&amp;doi=10.1126/science.aaf6407&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR9">9. <span class="element-citation">Zhou L, Zheng L, Hu K, Wang X, Zhang R, Zou Y, et al. SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites. <span><span class="ref-journal">Signal Transduc Target Ther. </span>2020;<span class="ref-vol">5</span>:80. doi: 10.1038/s41392-020-0172-4.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7311467/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32576812" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41392-020-0172-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Signal+Transduc+Target+Ther&amp;title=SUMOylation+stabilizes+hSSB1+and+enhances+the+recruitment+of+NBS1+to+DNA+damage+sites&amp;author=L+Zhou&amp;author=L+Zheng&amp;author=K+Hu&amp;author=X+Wang&amp;author=R+Zhang&amp;volume=5&amp;publication_year=2020&amp;pages=80&amp;doi=10.1038/s41392-020-0172-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR10">10. <span class="element-citation">Yang Y, Xia Z, Wang X, Zhao X, Sheng Z, Ye Y, et al. Small-molecule inhibitors targeting protein SUMOylation as novel anticancer compounds. <span><span class="ref-journal">Mol Pharmacol. </span>2018;<span class="ref-vol">9</span>:885–894. doi: 10.1124/mol.118.112300.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29784649" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1124%2Fmol.118.112300" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Pharmacol&amp;title=Small-molecule+inhibitors+targeting+protein+SUMOylation+as+novel+anticancer+compounds&amp;author=Y+Yang&amp;author=Z+Xia&amp;author=X+Wang&amp;author=X+Zhao&amp;author=Z+Sheng&amp;volume=9&amp;publication_year=2018&amp;pages=885-894&amp;doi=10.1124/mol.118.112300&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR11">11. <span class="element-citation">Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. <span><span class="ref-journal">Biomaterials. </span>2013;<span class="ref-vol">34</span>:8690–8707. doi: 10.1016/j.biomaterials.2013.07.100.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23953842" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.biomaterials.2013.07.100" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biomaterials&amp;title=Epidermal+growth+factor+receptor+targeting+in+cancer:+a+review+of+trends+and+strategies&amp;author=C+Yewale&amp;author=D+Baradia&amp;author=I+Vhora&amp;author=S+Patil&amp;author=A+Misra&amp;volume=34&amp;publication_year=2013&amp;pages=8690-8707&amp;pmid=23953842&amp;doi=10.1016/j.biomaterials.2013.07.100&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR12">12. <span class="element-citation">Habban Akhter M, Sateesh Madhav N, Ahmad J. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy. <span><span class="ref-journal">Artif Cells Nanomed Biotechnol. </span>2018;<span class="ref-vol">46</span>:1188–1198. doi: 10.1080/21691401.2018.1481863.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29991287" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F21691401.2018.1481863" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Artif+Cells+Nanomed+Biotechnol&amp;title=Epidermal+growth+factor+receptor+based+active+targeting:+a+paradigm+shift+towards+advance+tumor+therapy&amp;author=M+Habban+Akhter&amp;author=N+Sateesh+Madhav&amp;author=J+Ahmad&amp;volume=46&amp;publication_year=2018&amp;pages=1188-1198&amp;pmid=29991287&amp;doi=10.1080/21691401.2018.1481863&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR13">13. <span class="element-citation">Singh D, Attri BK, Gill RK, Bariwal J. Review on EGFR inhibitors: critical updates. <span><span class="ref-journal">Mini Rev Med Chem. </span>2016;<span class="ref-vol">16</span>:1134–1166. doi: 10.2174/1389557516666160321114917.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26996617" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2174%2F1389557516666160321114917" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mini+Rev+Med+Chem&amp;title=Review+on+EGFR+inhibitors:+critical+updates&amp;author=D+Singh&amp;author=BK+Attri&amp;author=RK+Gill&amp;author=J+Bariwal&amp;volume=16&amp;publication_year=2016&amp;pages=1134-1166&amp;pmid=26996617&amp;doi=10.2174/1389557516666160321114917&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR14">14. <span class="element-citation">Hoque M, Elmaghrabi YA, K&#x000f6;se M, Beevi SS, Jose J, Meneses-Salas E, et al. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells. <span><span class="ref-journal">FEBS J. </span>2020;<span class="ref-vol">287</span>:2961–2978. doi: 10.1111/febs.15186.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31869496" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Ffebs.15186" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+J&amp;title=Annexin+A6+improves+anti-migratory+and+anti-invasive+properties+of+tyrosine+kinase+inhibitors+in+EGFR+overexpressing+human+squamous+epithelial+cells&amp;author=M+Hoque&amp;author=YA+Elmaghrabi&amp;author=M+K&#x000f6;se&amp;author=SS+Beevi&amp;author=J+Jose&amp;volume=287&amp;publication_year=2020&amp;pages=2961-2978&amp;pmid=31869496&amp;doi=10.1111/febs.15186&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR15">15. <span class="element-citation">Pan Q, Lu Y, Xie L, Wu D, Liu R, Gao W, et al. Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy. <span><span class="ref-journal">Mol Pharm. </span>2023;<span class="ref-vol">20</span>:829–852. doi: 10.1021/acs.molpharmaceut.2c00792.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36588471" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Facs.molpharmaceut.2c00792" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Pharm&amp;title=Recent+advances+in+boosting+EGFR+tyrosine+kinase+inhibitors-based+cancer+therapy&amp;author=Q+Pan&amp;author=Y+Lu&amp;author=L+Xie&amp;author=D+Wu&amp;author=R+Liu&amp;volume=20&amp;publication_year=2023&amp;pages=829-852&amp;pmid=36588471&amp;doi=10.1021/acs.molpharmaceut.2c00792&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR16">16. <span class="element-citation">Boch T, K&#x000f6;hler J, Janning M, Loges S. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives. <span><span class="ref-journal">Cancer Biol Med. </span>2022;<span class="ref-vol">19</span>:1543–1564. doi: 10.20892/j.issn.2095-3941.2022.0540.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9724226/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36476337" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.20892%2Fj.issn.2095-3941.2022.0540" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Biol+Med&amp;title=Targeting+the+EGF+receptor+family+in+non-small+cell+lung+cancer-increased+complexity+and+future+perspectives&amp;author=T+Boch&amp;author=J+K&#x000f6;hler&amp;author=M+Janning&amp;author=S+Loges&amp;volume=19&amp;publication_year=2022&amp;pages=1543-1564&amp;pmid=36476337&amp;doi=10.20892/j.issn.2095-3941.2022.0540&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR17">17. <span class="element-citation">Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, et al. Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer. <span><span class="ref-journal">J Med Chem. </span>2022;<span class="ref-vol">65</span>:9662–9677. doi: 10.1021/acs.jmedchem.2c00704.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9340769/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35838760" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Facs.jmedchem.2c00704" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Chem&amp;title=Discovery+of+BLU-945,+a+reversible,+potent,+and+wild-type-sparing+next-generation+EGFR+mutant+inhibitor+for+treatment-resistant+non-small-cell+lung+cancer&amp;author=MS+Eno&amp;author=JD+Brubaker&amp;author=JE+Campbell&amp;author=C+De+Savi&amp;author=TJ+Guzi&amp;volume=65&amp;publication_year=2022&amp;pages=9662-9677&amp;pmid=35838760&amp;doi=10.1021/acs.jmedchem.2c00704&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR18">18. <span class="element-citation">Li D, Wang J, Liu C, Luo Y, Xu H, Wang Y, et al. Making the best use of available weapons for the inevitable rivalry-resistance to EGFR-TKIs. <span><span class="ref-journal">Biomedicines. </span>2023;<span class="ref-vol">11</span>:1141. doi: 10.3390/biomedicines11041141.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC10136294/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37189759" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fbiomedicines11041141" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&amp;title=Making+the+best+use+of+available+weapons+for+the+inevitable+rivalry-resistance+to+EGFR-TKIs&amp;author=D+Li&amp;author=J+Wang&amp;author=C+Liu&amp;author=Y+Luo&amp;author=H+Xu&amp;volume=11&amp;publication_year=2023&amp;pages=1141&amp;pmid=37189759&amp;doi=10.3390/biomedicines11041141&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR19">19. <span class="element-citation">Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, et al. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. <span><span class="ref-journal">Oncogene. </span>2013;<span class="ref-vol">32</span>:4427–4435. doi: 10.1038/onc.2012.446.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23045273" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fonc.2012.446" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Akt+kinase-interacting+protein1,+a+novel+therapeutic+target+for+lung+cancer+with+EGFR-activating+and+gatekeeper+mutations&amp;author=T+Yamada&amp;author=S+Takeuchi&amp;author=N+Fujita&amp;author=A+Nakamura&amp;author=W+Wang&amp;volume=32&amp;publication_year=2013&amp;pages=4427-4435&amp;pmid=23045273&amp;doi=10.1038/onc.2012.446&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR20">20. <span class="element-citation">Cui Y, Zhu T, Song X, Liu J, Liu S, Zhao R. Downregulation of caveolin-1 increased EGFR-TKIs sensitivity in lung adenocarcinoma cell line with EGFR mutation. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2018;<span class="ref-vol">495</span>:733–739. doi: 10.1016/j.bbrc.2017.11.075.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29137977" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.bbrc.2017.11.075" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Downregulation+of+caveolin-1+increased+EGFR-TKIs+sensitivity+in+lung+adenocarcinoma+cell+line+with+EGFR+mutation&amp;author=Y+Cui&amp;author=T+Zhu&amp;author=X+Song&amp;author=J+Liu&amp;author=S+Liu&amp;volume=495&amp;publication_year=2018&amp;pages=733-739&amp;pmid=29137977&amp;doi=10.1016/j.bbrc.2017.11.075&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR21">21. <span class="element-citation">Grewal T, Hoque M, Conway JRW, Reverter M, Wahba M, Beevi SS, et al. Annexin A6-a multifunctional scaffold in cell motility. <span><span class="ref-journal">Cell Adh Migr. </span>2017;<span class="ref-vol">11</span>:288–304. doi: 10.1080/19336918.2016.1268318.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5479450/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28060548" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F19336918.2016.1268318" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Adh+Migr&amp;title=Annexin+A6-a+multifunctional+scaffold+in+cell+motility&amp;author=T+Grewal&amp;author=M+Hoque&amp;author=JRW+Conway&amp;author=M+Reverter&amp;author=M+Wahba&amp;volume=11&amp;publication_year=2017&amp;pages=288-304&amp;pmid=28060548&amp;doi=10.1080/19336918.2016.1268318&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR22">22. <span class="element-citation">Keklikoglou I, Cianciaruso C, G&#x000fc;&#x000e7; E, Squadrito ML, Spring LM, Tazzyman S, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. <span><span class="ref-journal">Nat Cell Biol. </span>2019;<span class="ref-vol">21</span>:190–202. doi: 10.1038/s41556-018-0256-3.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6525097/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30598531" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41556-018-0256-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Cell+Biol&amp;title=Chemotherapy+elicits+pro-metastatic+extracellular+vesicles+in+breast+cancer+models&amp;author=I+Keklikoglou&amp;author=C+Cianciaruso&amp;author=E+G&#x000fc;&#x000e7;&amp;author=ML+Squadrito&amp;author=LM+Spring&amp;volume=21&amp;publication_year=2019&amp;pages=190-202&amp;pmid=30598531&amp;doi=10.1038/s41556-018-0256-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR23">23. <span class="element-citation">Koese M, Rentero C, Kota BP, Hoque M, Cairns R, Wood P, et al. Annexin A6 is a scaffold for PKC&#x003b1; to promote EGFR inactivation. <span><span class="ref-journal">Oncogene. </span>2013;<span class="ref-vol">32</span>:2858–2872. doi: 10.1038/onc.2012.303.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22797061" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fonc.2012.303" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Annexin+A6+is+a+scaffold+for+PKC&#x003b1;+to+promote+EGFR+inactivation&amp;author=M+Koese&amp;author=C+Rentero&amp;author=BP+Kota&amp;author=M+Hoque&amp;author=R+Cairns&amp;volume=32&amp;publication_year=2013&amp;pages=2858-2872&amp;pmid=22797061&amp;doi=10.1038/onc.2012.303&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR24">24. <span class="mixed-citation">Vil&#x000e1; de Muga S, Timpson P, Cubells L, Evans R, Hayes TE, Rentero C, et al. Annexin A6 inhibits Ras signalling in breast cancer cells. Oncogene.2009; 28: 363&#x02013;77. [<a href="https://pubmed.ncbi.nlm.nih.gov/18850003" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="CR25">25. <span class="element-citation">Francia G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, Hart IR. Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. <span><span class="ref-journal">Cancer Res. </span>1996;<span class="ref-vol">56</span>:3855–3858.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8752144" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Identification+by+differential+display+of+annexin-VI,+a+gene+differentially+expressed+during+melanoma+progression&amp;author=G+Francia&amp;author=SD+Mitchell&amp;author=SE+Moss&amp;author=AM+Hanby&amp;author=JF+Marshall&amp;volume=56&amp;publication_year=1996&amp;pages=3855-3858&amp;pmid=8752144&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR26">26. <span class="element-citation">Grewal T, Evans R, Rentero C, Tebar F, Cubells L, de Diego I, et al. Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. <span><span class="ref-journal">Oncogene. </span>2005;<span class="ref-vol">24</span>:5809–5820. doi: 10.1038/sj.onc.1208743.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15940262" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.onc.1208743" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Annexin+A6+stimulates+the+membrane+recruitment+of+p120GAP+to+modulate+Ras+and+Raf-1+activity&amp;author=T+Grewal&amp;author=R+Evans&amp;author=C+Rentero&amp;author=F+Tebar&amp;author=L+Cubells&amp;volume=24&amp;publication_year=2005&amp;pages=5809-5820&amp;pmid=15940262&amp;doi=10.1038/sj.onc.1208743&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR27">27. <span class="element-citation">Li T, Tao Z, Zhu Y, Liu X, Wang L, Du Y, et al. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. <span><span class="ref-journal">Cell Death Dis. </span>2021;<span class="ref-vol">12</span>:684. doi: 10.1038/s41419-021-03963-7.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8266800/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34238922" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41419-021-03963-7" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Death+Dis&amp;title=Exosomal+annexin+A6+induces+gemcitabine+resistance+by+inhibiting+ubiquitination+and+degradation+of+EGFR+in+triple-negative+breast+cancer&amp;author=T+Li&amp;author=Z+Tao&amp;author=Y+Zhu&amp;author=X+Liu&amp;author=L+Wang&amp;volume=12&amp;publication_year=2021&amp;pages=684&amp;pmid=34238922&amp;doi=10.1038/s41419-021-03963-7&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR28">28. <span class="element-citation">Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA. Dysregulation of the annexin family protein family is associated with prostate cancer progression. <span><span class="ref-journal">Am J Pathol. </span>2003;<span class="ref-vol">162</span>:255–261. doi: 10.1016/S0002-9440(10)63816-3.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1851111/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12507908" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0002-9440(10)63816-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=Dysregulation+of+the+annexin+family+protein+family+is+associated+with+prostate+cancer+progression&amp;author=W+Xin&amp;author=DR+Rhodes&amp;author=C+Ingold&amp;author=AM+Chinnaiyan&amp;author=MA+Rubin&amp;volume=162&amp;publication_year=2003&amp;pages=255-261&amp;pmid=12507908&amp;doi=10.1016/S0002-9440(10)63816-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR29">29. <span class="element-citation">Sakwe AM, Koumangoye R, Guillory B, Ochieng J. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions. <span><span class="ref-journal">Exp Cell Res. </span>2011;<span class="ref-vol">317</span>:823–837. doi: 10.1016/j.yexcr.2010.12.008.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3049817/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21185831" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.yexcr.2010.12.008" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Exp+Cell+Res&amp;title=Annexin+A6+contributes+to+the+invasiveness+of+breast+carcinoma+cells+by+influencing+the+organization+and+localization+of+functional+focal+adhesions&amp;author=AM+Sakwe&amp;author=R+Koumangoye&amp;author=B+Guillory&amp;author=J+Ochieng&amp;volume=317&amp;publication_year=2011&amp;pages=823-837&amp;pmid=21185831&amp;doi=10.1016/j.yexcr.2010.12.008&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR30">30. <span class="element-citation">Koumangoye RB, Nangami GN, Thompson PD, Agboto VK, Ochieng J, Sakwe AM. Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors. <span><span class="ref-journal">Mol Cancer. </span>2013;<span class="ref-vol">12</span>:167. doi: 10.1186/1476-4598-12-167.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3922904/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24354805" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2F1476-4598-12-167" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer&amp;title=Reduced+annexin+A6+expression+promotes+the+degradation+of+activated+epidermal+growth+factor+receptor+and+sensitizes+invasive+breast+cancer+cells+to+EGFR-targeted+tyrosine+kinase+inhibitors&amp;author=RB+Koumangoye&amp;author=GN+Nangami&amp;author=PD+Thompson&amp;author=VK+Agboto&amp;author=J+Ochieng&amp;volume=12&amp;publication_year=2013&amp;pages=167&amp;pmid=24354805&amp;doi=10.1186/1476-4598-12-167&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR31">31. <span class="element-citation">Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>:2115–2120. doi: 10.1182/blood.V97.7.2115.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11264179" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fblood.V97.7.2115" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Identification+of+novel+markers+for+monitoring+minimal+residual+disease+in+acute+lymphoblastic+leukemia&amp;author=JS+Chen&amp;author=E+Coustan-Smith&amp;author=T+Suzuki&amp;author=GA+Neale&amp;author=K+Mihara&amp;volume=97&amp;publication_year=2001&amp;pages=2115-2120&amp;pmid=11264179&amp;doi=10.1182/blood.V97.7.2115&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR32">32. <span class="element-citation">Luo M, Huang Z, Yang X, Chen Y, Jiang J, Zhang L, et al. PHLDB2 mediates cetuximab resistance via interacting with EGFR in latent metastasis of colorectal cancer. <span><span class="ref-journal">Cell Mol Gastroenterol Hepatol. </span>2022;<span class="ref-vol">13</span>:1223–1242. doi: 10.1016/j.jcmgh.2021.12.011.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8881668/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34952201" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jcmgh.2021.12.011" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Mol+Gastroenterol+Hepatol&amp;title=PHLDB2+mediates+cetuximab+resistance+via+interacting+with+EGFR+in+latent+metastasis+of+colorectal+cancer&amp;author=M+Luo&amp;author=Z+Huang&amp;author=X+Yang&amp;author=Y+Chen&amp;author=J+Jiang&amp;volume=13&amp;publication_year=2022&amp;pages=1223-1242&amp;pmid=34952201&amp;doi=10.1016/j.jcmgh.2021.12.011&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR33">33. <span class="element-citation">Yang Y, Liang Z, Xia Z, Wang X, Ma Y, Sheng Z, et al. SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways. <span><span class="ref-journal">Cell Commun Signa. </span>2019;<span class="ref-vol">17</span>:82. doi: 10.1186/s12964-019-0392-9.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6659289/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31345225" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs12964-019-0392-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Commun+Signa&amp;title=SAE1+promotes+human+glioma+progression+through+activating+AKT+SUMOylation-mediated+signaling+pathways&amp;author=Y+Yang&amp;author=Z+Liang&amp;author=Z+Xia&amp;author=X+Wang&amp;author=Y+Ma&amp;volume=17&amp;publication_year=2019&amp;pages=82&amp;doi=10.1186/s12964-019-0392-9&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR34">34. <span class="element-citation">Tammsalu T, Matic I, Jaffray EG, Ibrahim AF, Tatham MH, Hay RT. Proteome-wide identification of SUMO modification sites by mass spectrometry. <span><span class="ref-journal">Nat Protoc. </span>2015;<span class="ref-vol">10</span>:1374–1388. doi: 10.1038/nprot.2015.095.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26292070" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnprot.2015.095" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Protoc&amp;title=Proteome-wide+identification+of+SUMO+modification+sites+by+mass+spectrometry&amp;author=T+Tammsalu&amp;author=I+Matic&amp;author=EG+Jaffray&amp;author=AF+Ibrahim&amp;author=MH+Tatham&amp;volume=10&amp;publication_year=2015&amp;pages=1374-1388&amp;pmid=26292070&amp;doi=10.1038/nprot.2015.095&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR35">35. <span class="element-citation">Yu Y, Sikorski P, Bowman-Gholston C, Cacciabeve N, Nelson KE, Pieper R. Diagnosing inflammation and infection in the urinary system via proteomics. <span><span class="ref-journal">J Transl Med. </span>2015;<span class="ref-vol">13</span>:111. doi: 10.1186/s12967-015-0475-3.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4396075/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25889401" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs12967-015-0475-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Transl+Med&amp;title=Diagnosing+inflammation+and+infection+in+the+urinary+system+via+proteomics&amp;author=Y+Yu&amp;author=P+Sikorski&amp;author=C+Bowman-Gholston&amp;author=N+Cacciabeve&amp;author=KE+Nelson&amp;volume=13&amp;publication_year=2015&amp;pages=111&amp;pmid=25889401&amp;doi=10.1186/s12967-015-0475-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR36">36. <span class="element-citation">Wang X, He Y, Ye Y, Zhao X, Deng S, He G, et al. SILAC-based quantitative MS approach for real-time recording protein-mediated cell-cell interactions. <span><span class="ref-journal">Sci Rep. </span>2018;<span class="ref-vol">8</span>:8441. doi: 10.1038/s41598-018-26262-2.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5981645/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29855483" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41598-018-26262-2" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci+Rep&amp;title=SILAC-based+quantitative+MS+approach+for+real-time+recording+protein-mediated+cell-cell+interactions&amp;author=X+Wang&amp;author=Y+He&amp;author=Y+Ye&amp;author=X+Zhao&amp;author=S+Deng&amp;volume=8&amp;publication_year=2018&amp;pages=8441&amp;pmid=29855483&amp;doi=10.1038/s41598-018-26262-2&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR37">37. <span class="element-citation">He Y, Wang X, Lu W, Zhang D, Huang L, Luo Y, et al. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. <span><span class="ref-journal">Cell Death Dis. </span>2022;<span class="ref-vol">13</span>:118. doi: 10.1038/s41419-022-04576-4.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8816910/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35121728" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41419-022-04576-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Death+Dis&amp;title=PGK1+contributes+to+tumorigenesis+and+sorafenib+resistance+of+renal+clear+cell+carcinoma+via+activating+CXCR4/ERK+signaling+pathway+and+accelerating+glycolysis&amp;author=Y+He&amp;author=X+Wang&amp;author=W+Lu&amp;author=D+Zhang&amp;author=L+Huang&amp;volume=13&amp;publication_year=2022&amp;pages=118&amp;pmid=35121728&amp;doi=10.1038/s41419-022-04576-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR38">38. <span class="element-citation">Zhang Z, Gao W, Zhou L, Chen Y, Qin S, Zhang L, et al. Repurposing brigatinib for the treatment of colorectal cancer based on inhibition of ER-phagy. <span><span class="ref-journal">Theranostics. </span>2019;<span class="ref-vol">9</span>:4878–4892. doi: 10.7150/thno.36254.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6691391/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31410188" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.7150%2Fthno.36254" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=Repurposing+brigatinib+for+the+treatment+of+colorectal+cancer+based+on+inhibition+of+ER-phagy&amp;author=Z+Zhang&amp;author=W+Gao&amp;author=L+Zhou&amp;author=Y+Chen&amp;author=S+Qin&amp;volume=9&amp;publication_year=2019&amp;pages=4878-4892&amp;pmid=31410188&amp;doi=10.7150/thno.36254&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR39">39. <span class="element-citation">Chakraborty P, Ahil SB, Jamma T, Yogeeswari P. Combining structure-based and 3D QSAR pharmacophore models to discover diverse ligands against EGFR in oral cancer. <span><span class="ref-journal">Future Med Chem. </span>2022;<span class="ref-vol">14</span>:463–478. doi: 10.4155/fmc-2021-0205.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35167330" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4155%2Ffmc-2021-0205" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Future+Med+Chem&amp;title=Combining+structure-based+and+3D+QSAR+pharmacophore+models+to+discover+diverse+ligands+against+EGFR+in+oral+cancer&amp;author=P+Chakraborty&amp;author=SB+Ahil&amp;author=T+Jamma&amp;author=P+Yogeeswari&amp;volume=14&amp;publication_year=2022&amp;pages=463-478&amp;pmid=35167330&amp;doi=10.4155/fmc-2021-0205&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR40">40. <span class="element-citation">Todsaporn D, Mahalapbutr P, Poo-Arporn RP, Choowongkomon K, Rungrotmongkol T. Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR. <span><span class="ref-journal">Comput Biol Med. </span>2022;<span class="ref-vol">147</span>:105787. doi: 10.1016/j.compbiomed.2022.105787.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35803080" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.compbiomed.2022.105787" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Comput+Biol+Med&amp;title=Structural+dynamics+and+kinase+inhibitory+activity+of+three+generations+of+tyrosine+kinase+inhibitors+against+wild-type,+L858R/T790M,+and+L858R/T790M/C797S+forms+of+EGFR&amp;author=D+Todsaporn&amp;author=P+Mahalapbutr&amp;author=RP+Poo-Arporn&amp;author=K+Choowongkomon&amp;author=T+Rungrotmongkol&amp;volume=147&amp;publication_year=2022&amp;pages=105787&amp;pmid=35803080&amp;doi=10.1016/j.compbiomed.2022.105787&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR41">41. <span class="element-citation">Garc&#x000ed;a-Melero A, Reverter M, Hoque M, Meneses-Salas E, Koese M, Conway JR, et al. Annexin A6 and late endosomal cholesterol modulate integrin recycling and cell migration. <span><span class="ref-journal">J Biol Chem. </span>2020;<span class="ref-vol">291</span>:1320–1335. doi: 10.1074/jbc.M115.683557.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4714218/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26578516" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1074%2Fjbc.M115.683557" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Annexin+A6+and+late+endosomal+cholesterol+modulate+integrin+recycling+and+cell+migration&amp;author=A+Garc&#x000ed;a-Melero&amp;author=M+Reverter&amp;author=M+Hoque&amp;author=E+Meneses-Salas&amp;author=M+Koese&amp;volume=291&amp;publication_year=2020&amp;pages=1320-1335&amp;doi=10.1074/jbc.M115.683557&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR42">42. <span class="element-citation">Qi H, Liu S, Guo C, Wang J, Greenaway FT, Sun MZ. Role of annexin A6 in cancer. <span><span class="ref-journal">Oncol Lett. </span>2015;<span class="ref-vol">10</span>:1947–1952. doi: 10.3892/ol.2015.3498.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4579822/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26622779" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3892%2Fol.2015.3498" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncol+Lett&amp;title=Role+of+annexin+A6+in+cancer&amp;author=H+Qi&amp;author=S+Liu&amp;author=C+Guo&amp;author=J+Wang&amp;author=FT+Greenaway&amp;volume=10&amp;publication_year=2015&amp;pages=1947-1952&amp;pmid=26622779&amp;doi=10.3892/ol.2015.3498&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR43">43. <span class="element-citation">O'Sullivan D, Dowling P, Joyce H, McAuley E, McCann A, Henry M, et al. A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer. <span><span class="ref-journal">Br J Cancer. </span>2017;<span class="ref-vol">117</span>:1326–1335. doi: 10.1038/bjc.2017.306.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5672937/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28881357" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fbjc.2017.306" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=A+novel+inhibitory+anti-invasive+MAb+isolated+using+phenotypic+screening+highlights+AnxA6+as+a+functionally+relevant+target+protein+in+pancreatic+cancer&amp;author=D+O'Sullivan&amp;author=P+Dowling&amp;author=H+Joyce&amp;author=E+McAuley&amp;author=A+McCann&amp;volume=117&amp;publication_year=2017&amp;pages=1326-1335&amp;pmid=28881357&amp;doi=10.1038/bjc.2017.306&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR44">44. <span class="element-citation">Sheng Z, Wang X, Ma Y, Zhang D, Yang Y, Zhang P, et al. MS-based strategies for identification of protein SUMOylation modification. <span><span class="ref-journal">Electrophoresis. </span>2018;<span class="ref-vol">40</span>:2877–2887. doi: 10.1002/elps.201900100.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6899701/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31216068" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Felps.201900100" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Electrophoresis&amp;title=MS-based+strategies+for+identification+of+protein+SUMOylation+modification&amp;author=Z+Sheng&amp;author=X+Wang&amp;author=Y+Ma&amp;author=D+Zhang&amp;author=Y+Yang&amp;volume=40&amp;publication_year=2018&amp;pages=2877-2887&amp;doi=10.1002/elps.201900100&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR45">45. <span class="element-citation">Bao J, Qin M, Mahaman YAR, Zhang B, Huang F, Zeng K, et al. BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2018;<span class="ref-vol">115</span>:3954–3959. doi: 10.1073/pnas.1800498115.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5899489/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29581300" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.1800498115" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=BACE1+SUMOylation+increases+its+stability+and+escalates+the+protease+activity+in+Alzheimer's+disease&amp;author=J+Bao&amp;author=M+Qin&amp;author=YAR+Mahaman&amp;author=B+Zhang&amp;author=F+Huang&amp;volume=115&amp;publication_year=2018&amp;pages=3954-3959&amp;pmid=29581300&amp;doi=10.1073/pnas.1800498115&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR46">46. <span class="element-citation">Mei L, Yuan L, Shi W, Fan S, Tang C, Fan X, et al. SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions. <span><span class="ref-journal">Cancer Lett. </span>2017;<span class="ref-vol">386</span>:1–11. doi: 10.1016/j.canlet.2016.11.009.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27847303" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.canlet.2016.11.009" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Lett&amp;title=SUMOylation+of+large+tumor+suppressor+1+at+Lys751+attenuates+its+kinase+activity+and+tumor-suppressor+functions&amp;author=L+Mei&amp;author=L+Yuan&amp;author=W+Shi&amp;author=S+Fan&amp;author=C+Tang&amp;volume=386&amp;publication_year=2017&amp;pages=1-11&amp;pmid=27847303&amp;doi=10.1016/j.canlet.2016.11.009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR47">47. <span class="element-citation">Qu Y, Chen Q, Lai X, Zhu C, Chen C, Zhao X, et al. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos. <span><span class="ref-journal">Mol Cancer. </span>2014;<span class="ref-vol">13</span>:95. doi: 10.1186/1476-4598-13-95.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4021559/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24775912" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2F1476-4598-13-95" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer&amp;title=SUMOylation+of+Grb2+enhances+the+ERK+activity+by+increasing+its+binding+with+Sos&amp;author=Y+Qu&amp;author=Q+Chen&amp;author=X+Lai&amp;author=C+Zhu&amp;author=C+Chen&amp;volume=13&amp;publication_year=2014&amp;pages=95&amp;pmid=24775912&amp;doi=10.1186/1476-4598-13-95&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR48">48. <span class="element-citation">Fu J, Yu J, Zhang X, Chang Y, Fan H, Dong M, et al. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFR<sup>L858R/T790M</sup> inhibitors. <span><span class="ref-journal">J Enzyme Inhib Med Chem. </span>2023;<span class="ref-vol">38</span>:2205605. doi: 10.1080/14756366.2023.2205605.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC10150624/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37106478" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F14756366.2023.2205605" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Enzyme+Inhib+Med+Chem&amp;title=Design,+synthesis,+and+biological+evaluation+of+pyrido[2,3-d]pyrimidine+and+thieno[2,3-d]pyrimidine+derivatives+as+novel+EGFRL858R/T790M+inhibitors&amp;author=J+Fu&amp;author=J+Yu&amp;author=X+Zhang&amp;author=Y+Chang&amp;author=H+Fan&amp;volume=38&amp;publication_year=2023&amp;pages=2205605&amp;pmid=37106478&amp;doi=10.1080/14756366.2023.2205605&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR49">49. <span class="element-citation">Ullas B, Shrinidhi N, Mansi S, Narayan S, Parveen J, Surender D, et al. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations. <span><span class="ref-journal">J Cancer Res Clin Oncol. </span>2023;<span class="ref-vol">149</span>:1541–1549. doi: 10.1007/s00432-022-04033-x.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35581383" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00432-022-04033-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cancer+Res+Clin+Oncol&amp;title=All+EGFR+mutations+are+(not)+created+equal:+focus+on+uncommon+EGFR+mutations&amp;author=B+Ullas&amp;author=N+Shrinidhi&amp;author=S+Mansi&amp;author=S+Narayan&amp;author=J+Parveen&amp;volume=149&amp;publication_year=2023&amp;pages=1541-1549&amp;pmid=35581383&amp;doi=10.1007/s00432-022-04033-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR50">50. <span class="element-citation">Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, et al. Tyrosine kinase inhibitor activity in patients with NSCLC harboring uncommon EGFR mutations: a retrospective international cohort study (UpSwinG) <span><span class="ref-journal">Oncologist. </span>2022;<span class="ref-vol">27</span>:255–265. doi: 10.1093/oncolo/oyac022.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8982383/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35274704" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Foncolo%2Foyac022" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=Tyrosine+kinase+inhibitor+activity+in+patients+with+NSCLC+harboring+uncommon+EGFR+mutations:+a+retrospective+international+cohort+study+(UpSwinG)&amp;author=S+Popat&amp;author=TC+Hsia&amp;author=JY+Hung&amp;author=HA+Jung&amp;author=JY+Shih&amp;volume=27&amp;publication_year=2022&amp;pages=255-265&amp;pmid=35274704&amp;doi=10.1093/oncolo/oyac022&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR51">51. <span class="element-citation">Huo D, Wang H, Qin Z, Tian Y, Yan A. Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR. <span><span class="ref-journal">Mol Divers. </span>2022;<span class="ref-vol">26</span>:1715–1730. doi: 10.1007/s11030-021-10300-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34636023" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs11030-021-10300-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Divers&amp;title=Building+2D+classification+models+and+3D+CoMSIA+models+on+small-molecule+inhibitors+of+both+wild-type+and+T790M/L858R+double-mutant+EGFR&amp;author=D+Huo&amp;author=H+Wang&amp;author=Z+Qin&amp;author=Y+Tian&amp;author=A+Yan&amp;volume=26&amp;publication_year=2022&amp;pages=1715-1730&amp;pmid=34636023&amp;doi=10.1007/s11030-021-10300-9&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR52">52. <span class="element-citation">Duggirala KB, Lee Y, Lee K. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations. <span><span class="ref-journal">Biomol Ther (Seoul) </span>2022;<span class="ref-vol">30</span>:19–27. doi: 10.4062/biomolther.2021.047.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8724843/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34074804" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4062%2Fbiomolther.2021.047" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biomol+Ther+(Seoul)&amp;title=Chronicles+of+EGFR+Tyrosine+Kinase+Inhibitors:+Targeting+EGFR+C797S+Containing+Triple+Mutations&amp;author=KB+Duggirala&amp;author=Y+Lee&amp;author=K+Lee&amp;volume=30&amp;publication_year=2022&amp;pages=19-27&amp;pmid=34074804&amp;doi=10.4062/biomolther.2021.047&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR53">53. <span class="element-citation">Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. <span><span class="ref-journal">Mol Cancer. </span>2018;<span class="ref-vol">17</span>:53. doi: 10.1186/s12943-018-0793-1.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5817859/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29455669" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs12943-018-0793-1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer&amp;title=EGFR-TKIs+resistance+via+EGFR-independent+signaling+pathways&amp;author=Q+Liu&amp;author=S+Yu&amp;author=W+Zhao&amp;author=S+Qin&amp;author=Q+Chu&amp;volume=17&amp;publication_year=2018&amp;pages=53&amp;pmid=29455669&amp;doi=10.1186/s12943-018-0793-1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR54">54. <span class="element-citation">Yu JJ, Zhou DD, Yang XX, Cui B, Tan FW, Wang J, et al. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. <span><span class="ref-journal">Nat Commun. </span>2020;<span class="ref-vol">11</span>:3660. doi: 10.1038/s41467-020-17385-0.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7374170/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32694521" ref="reftype=pubmed&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41467-020-17385-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Commun&amp;title=TRIB3-EGFR+interaction+promotes+lung+cancer+progression+and+defines+a+therapeutic+target&amp;author=JJ+Yu&amp;author=DD+Zhou&amp;author=XX+Yang&amp;author=B+Cui&amp;author=FW+Tan&amp;volume=11&amp;publication_year=2020&amp;pages=3660&amp;pmid=32694521&amp;doi=10.1038/s41467-020-17385-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10391975&amp;issue-id=425134&amp;journal-id=221&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Cell Communication and Signaling : CCS</span> are provided here courtesy of <strong>BMC</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10391975/pdf/12964_2023_Article_1217.pdf" class="int-view">PDF (4.4M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10391975/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10391975/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10391975" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10391975%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="Wlxyz964DxFAS5GVkguGTCJ9ZG93nVMcSjGeKegnGqgVj4UaMrWdJ7dSxPAoi2eD">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10391975%2F&amp;text=SUMOylation%20of%20AnxA6%20facilitates%20EGFR-PKC%003B1%20complex%20formation%20to%20suppress%20epithelial%20cancer%20growth" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10391975%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391975/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10391975/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37528485/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10391975/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37528485/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10391975/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10391975/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript">var ncbimedia_baseDir = "/corehtml/pmc/ncbimedia/";</script><script type="text/javascript" src="/corehtml/pmc/ncbimedia/ncbimedia.js"></script><script type="text/javascript" src="/corehtml/pmc/ncbimedia/pmcmedia.js"></script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC10391975/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
